A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors

A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors - ARTISTRY-1

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02799095

Enrollment

243

Registered

2016-06-14

Start date

2016-09-14

Completion date

2023-08-02

Last updated

2025-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Solid Tumors

Keywords

Immunotherapy, IL-2, Interleukin-2, Solid tumors, Melanoma, Renal cell carcinoma, Non-small-cell lung cancer, Squamous cell carcinoma of the head and neck, in combination with pembrolizumab

Brief summary

To better understand the safety and tolerability of ALKS 4230 in humans

Detailed description

To investigate the safety and tolerability of ALKS 4230, determine the recommended Phase 2 dose (RP2D) and assess anti-tumor activity in Monotherapy and ALKS 4230 in Combination with pembrolizumab.

Interventions

DRUGALKS 4230

Intravenous (IV) infusion over 30 minutes given daily for 5 consecutive days followed by an off-treatment period

DRUGALKS 4230 + pembrolizumab

IV infusion of ALKS 4230 over 30 minutes given daily for 5 consecutive days followed by an off-treatment period; pembrolizumab administered IV once with ALKS 4230 on the first day of each cycle

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* For Part A, the subject has histological or cytological evidence of a solid tumor; for Part B, the subject has a diagnosis of melanoma or renal cell carcinoma * All subjects must have advanced solid tumors that have returned after treatment with established approved therapies or be intolerant of established therapies * Subjects enrolled in Part B or Part C must have at least 1 lesion that may qualify as a target lesion * Subject can move around on their own, has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and has an estimated life expectancy of at least 3 months * Subject must have adequate hematologic reserve * Subjects must have adequate liver function * Subjects must have adequate kidney function * Subjects must be recovered from the effects of any prior chemotherapy, immunotherapy, other prior systemic anticancer therapy, radiotherapy or surgery * Subjects who have received investigational agents must wait at least 4 weeks * Females of childbearing potential must have a negative pregnancy test within 7 days of the start of treatment and on Day 1 before the first dose is administered. A female not of childbearing potential is one who has undergone bilateral oophorectomies or who is postmenopausal, defined as \>45 years of age and without a menstrual period for 12 consecutive months * Meets contraceptive requirements defined in the protocol * Additional criteria may apply

Exclusion criteria

* Subject is currently pregnant or breastfeeding, or is planning to become pregnant during the study * Subjects with an active infection or with a fever \>/= 38.5 degrees C within 3 days of the first scheduled day of dosing for Cycle 1 * Subjects with active or symptomatic central nervous system metastases are excluded. Subjects with central nervous system metastases are eligible for the study if the metastases have been treated by surgery and/or radiation therapy, the subject is off corticosteroids for at least 2 weeks and the subject is neurologically stable * Subjects have a mean QT interval corrected by the Fridericia Correction formula value of \>470 msec (in females) or \>450 msec (in males) * Subjects with known hypersensitivity to any components of ALKS 4230 * Subjects with known hypersensitivity to any components of pembrolizumab (for patients in combination arm only) * Subjects who require pharmacologic doses of corticosteroids; replacement doses, topical, ophthalmologic, and inhalational steroids are permitted * Subjects who developed autoimmune disorders while on prior immunotherapy, including pneumonitis, nephritis, and neuropathy * Subjects with any other concurrent uncontrolled illness, including mental illness or substance abuse, which may interfere with the ability of the subject to cooperate and participate in the study * The subject is known to be positive for human immunodeficiency virus (HIV), hepatitis B or C, or active tuberculosis, or has a known history of tuberculosis * Subjects with dyspnea at rest of requiring oxygen therapy * Subjects active autoimmune disease requiring systemic treatment within the past 30 days * Subjects who received radiotherapy within the last 4 weeks before start of study treatment administration with the exception of limited field palliative radiotherapy * Subjects who have received systemic immunomodulatory agents within 28 days prior to C1D1. * Subjects who have received administration of a live, attenuated vaccine within 4 weeks of Cycle 1, Day1. * Prior solid organ and/or non-autologous hematopoietic stem cell or bone marrow transplant recipients * Subjects who have received prior IL-2 based or IL-15 based cytokine therapy * Additional criteria may apply

Design outcomes

Primary

Measure	Time frame	Description
Part A: Number of Participants With Dose-limiting Toxicities (DLTs) Based on Common Terminology Criteria for Adverse Events (CTCAE)	Cycle 1 Day 1 through Cycle 2 Day 15 (Cycle 1 length = 14 days; Cycle 2 length= 21 days)	DLT was defined by any of following events possibly, probably, or definitely related to ALKS 4230: Grade 4 neutrophil count decreased (neutropenia); Febrile neutropenia; CTCAE Grade 4 thrombocytopenia; Thrombocytopenia; Any Grade 3 cardiac or central nervous system toxicity; Liver transaminase elevation higher than 8\upper limit of normal (ULN) or total bilirubin higher than 6\ULN; Grade 4 hypoalbuminemia; Fever more than (\>) 40 degree Celsius (°C) sustained for \>24 hours; Hypotension required the use of pressors or prolonged hospitalization (\>48 hours) for hypotension requiring medical intervention; Grade 3 or higher electrolyte abnormalities; Increase in amylase or lipase; Grade 3 or higher nausea, vomiting, or diarrhea; Any other Grade 4 nonhematologic toxicity or any other Grade 3 non-hematologic toxicity; Any other toxicity or adverse event (AE) not defined above that resulted in participant removal from the study or discontinuation of dosing by the Investigator.
Parts A, B, and C: Number of Participants With Treatment-emergent Adverse Events (TEAEs)	From first dose of study drug until 30 days after last dose (up to 10 months for Part A; up to 41.3 months for Part B; up to 51.5 months for Part C)	TEAEs were defined as AEs that were newly occurring or worsening from the time of the first dose of study drug. An AE was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product.
Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	From first dose of study drug until 30 days after last dose (up to 10 months for Part A; up to 41.3 months for Part B; up to 51.5 months for Part C)	TEAEs were defined as AEs that were newly occurring or worsening from the time of the first dose of study drug. Severity was graded according to the National Cancer Institute (NCI) CTCAE (version 4.03) where, Grade 1: Mild- asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2: Moderate- minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL) Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL. Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death related to AE. As planned, Grades 1 and 2 were combined for reporting.
Parts B and C: Overall Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1	From first dose of study drug up to 40.3 months for Part B and up to 50.5 months for Part C	ORR rate was defined as the percentage of participants with objective evidence of CR or PR based on RECIST v1.1. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeters (mm). Partial Response (PR): At least a 30 percent (%) decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Secondary

Measure	Time frame	Description
Parts A, B, and C: Proportion of Positive Anti-Nemvaleukin Alfa Antibodies (ADA)	From first dose of study drug up to 9 months (for Part A); up to 40.3 months (for Part B); up to 50.5 months (for Part C)	Overall proportion was calculated as: Number of participants (overall positive)/total number of participants in the cohort. Overall positive: Participants with at least 1 treatment-emergent ADA positive sample at any time during the treatment period.
Parts A, B, and C: Immune ORR (iORR) Based on Immune RECIST (iRECIST)	From first dose of study drug up to 9 months for Part A; up to 40.3 months for Part B; up to 50.5 months for Part C	iORR was defined as the percentage of participants with objective evidence of immune CR (iCR) or immune PR (iPR) based on iRECIST guidelines.
Parts A, B, and C: Disease Control Rate (DCR) Based on RECIST v.1.1	From first dose of study drug up to 9 months for Part A; up to 40.3 months for Part B; up to 50.5 months for Part C	Disease control rate was defined as the percentage of participants with objective evidence of CR, PR, or SD based on RECIST v.1.1. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
Parts A, B, and C: Immune DCR (iDCR) Based on iRECIST v1.1	From first dose of study drug up to 9 months for Part A; up to 40.3 months for Part B; up to 50.5 months for Part C	iDCR was defined as the percentage of participants with objective evidence of iCR, iPR (where iCR or iPR required confirmation), or immune stable disease (iSD) (where the iSD requires to occur at Cycle 4 or later).
Parts B, and C: Duration of Response (DOR) Based on RECIST v1.1	From the first documentation of response (CR or PR) to the first documentation of objective tumor progression or death due to any cause (up to 40.3 months for Part B and up to 50.5 months for Part C)	Duration of response was defined as the time from the first documentation of response (CR or PR) to the first documentation of objective tumor progression or death due to any cause. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. PD: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Parts B, and C: Immune DOR (iDOR) Based on iRECIST	From first dose of study drug up to 40.3 months for Part B; up to 50.5 months for Part C	iDOR was defined as the time from the first documentation of response (iCR or iPR) to the first documentation of objective tumor progression (immune confirmed progressive disease \[iCPD\]) or death due to any cause based on iRECIST.
Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 and 2 Day 1: 0, 0.5, 1, 2, 4, 8, 16, and 24 hours post-dose; Cycle 1 Day 5: 0, 0.5, 1, 2, 4, 8, 16, 24, and 72 hours post-dose; Cycle 2 Day 5: 0, 0.5, 1, 2, 4, 8, 16, 24, 72, and 240 hours post-dose	Cycle 1 length = 14 days for Part A and 21 days for Part B and C; Cycle 2 length= 21 days for all parts.
Part B and Part C Cohorts C5, C6, C7: Immune DRR (iDRR) Based on iRECIST	From first dose of study drug up to 40.3 months for Part B; up to 50.5 months for Part C	iDRR was defined as the percentage of participants with an objective response (complete or partial response per iRECIST) lasting continuously for 6 months and starting any time within 12 months of initiating the study drug.
Part B and Part C Cohorts C5, C6, C7: Progression-free Survival (PFS) Based on RECIST v.1.1	From first dose of study drug up to the first documentation of objective tumor progression or death due to any cause (up to 40.3 months for Part B and up to 50.5 months for Part C)	Progression-free survival was defined as the time from the first dose of nemvaleukin to the first documentation of objective tumor progression or death due to any cause. PD: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Part B and Part C Cohorts C5, C6, C7: Immune PFS (iPFS)	From first dose of study drug up to 40.3 months for Part B; up to 50.5 months for Part C	iPFS was defined as the time from the first dose of study medication to the first documentation of objective tumor progression based on iRECIST (immune confirmed progressive disease \[iCPD\]) or death due to any cause.
Parts A, B and C: Maximum Cell Count of Whole Blood FoxP3+ T Cells (Tregs), Total Cluster of Differentiation (CD)8+ T Cells and Natural Killer (NK) Cells	Cycle 1 Day 1 (Cycle 1 length = 14 days for Part A and 21 days for Part B and C)	—
Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	Cycle 1 Days 1 and 5; Cycle 2 Days 1 and 5 (Cycle 1 length = 14 days for Part A and 21 days for Part B and C; Cycle 2 length= 21 days for all parts)	—
Part B and Part C Cohorts C5, C6, C7: Durable Response Rate (DRR) Based on RECIST v.1.1	From first dose of study drug up to 40.3 months for Part B; up to 50.5 months for Part C	DRR was defined as the percentage of participants with an objective response (complete or partial response per RECIST 1.1) lasting continuously for 6 months and starting any time within 12 months of initiating the study drug.
Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 1 and 2 Day 1: 0, 0.5, 1, 2, 4, 8, 16, and 24 hours post-dose; Cycle 1 Day 5: 0, 0.5, 1, 2, 4, 8, 16, 24, and 72 hours post-dose; Cycle 2 Day 5: 0, 0.5, 1, 2, 4, 8, 16, 24, 72, and 240 hours post-dose	Cycle 1 length = 14 days for Part A and 21 days for Part B and C; Cycle 2 length= 21 days for all parts.
Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 1 and 2 Day 1: 0, 0.5, 1, 2, 4, 8, 16, and 24 hours post-dose; Cycle 1 Day 5: 0, 0.5, 1, 2, 4, 8, 16, 24, and 72 hours post-dose; Cycle 2 Day 5: 0, 0.5, 1, 2, 4, 8, 16, 24, 72, and 240 hours post-dose	Cycle 1 length = 14 days for Part A and 21 days for Part B and C; Cycle 2 length= 21 days for all parts.
Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 1 and 2 Day 1: 0, 0.5, 1, 2, 4, 8, 16, and 24 hours post-dose; Cycle 1 Day 5: 0, 0.5, 1, 2, 4, 8, 16, 24, and 72 hours post-dose; Cycle 2 Day 5: 0, 0.5, 1, 2, 4, 8, 16, 24, 72, and 240 hours post-dose	Cycle 1 length = 14 days for Part A and 21 days for Part B and C; Cycle 2 length= 21 days for all parts.

Countries

Australia, Belgium, Canada, Poland, South Korea, Spain, United States

Participant flow

Recruitment details

The study was conducted at 47 investigative sites in the United States, Spain, Canada, South Korea, Australia, Belgium, and Poland.

Pre-assignment details

A total of 243 participants were enrolled in this 3-part study (Parts A, B and C) to receive nemvaleukin alfa (ALKS 4230) either as monotherapy or in combination with pembrolizumab. Selected participants (43) enrolled in Monotherapy Parts A and B, and who did not demonstrate clinical benefit were eligible to rollover to Combination Therapy Part C and were rolled over in Part C, Cohort 4.

Participants by arm

Arm	Count
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg Participants with advanced solid tumors received nemvaleukin alfa 0.1 mcg/kg IV infusion administration daily from Days 1 to 5 in Cycle 1 (Cycle length = 14 days) and then in Cycle 2 and subsequent cycles (each Cycle length = 21 days) until disease progression or the participant met any discontinuation criteria.	5
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg Participants with advanced solid tumors received nemvaleukin alfa 0.3 mcg/kg IV infusion administration daily from Days 1 to 5 in Cycle 1 (Cycle length = 14 days) and then in Cycle 2 and subsequent cycles (each Cycle length = 21 days) until disease progression or the participant met any discontinuation criteria.	4
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg Participants with advanced solid tumors received nemvaleukin alfa 1 mcg/kg IV infusion administration daily from Days 1 to 5 in Cycle 1 (Cycle length = 14 days) and then in Cycle 2 and subsequent cycles (each Cycle length = 21 days) until disease progression or the participant met any discontinuation criteria.	7
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg Participants with advanced solid tumors received nemvaleukin alfa 3 mcg/kg IV infusion administration daily from Days 1 to 5 in Cycle 1 (Cycle length = 14 days) and then in Cycle 2 and subsequent cycles (each Cycle length = 21 days) until disease progression or the participant met any discontinuation criteria.	8
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg Participants with advanced solid tumors received nemvaleukin alfa 6 mcg/kg IV infusion administration daily from Days 1 to 5 in Cycle 1 (Cycle length = 14 days) and then in Cycle 2 and subsequent cycles (each Cycle length = 21 days) until disease progression or the participant met any discontinuation criteria.	12
Part A, Dose Escalation: Nemvaleukin Alfa 8 mcg/kg Participants with advanced solid tumors received nemvaleukin alfa 8 mcg/kg IV infusion administration daily from Days 1 to 5 in Cycle 1 (Cycle length = 14 days) and then in Cycle 2 and subsequent cycles (each Cycle length = 21 days) until disease progression or the participant met any discontinuation criteria.	3
Part A, Dose Escalation: Nemvaleukin Alfa 10 mcg/kg Participants with advanced solid tumors received nemvaleukin alfa 10 mcg/kg IV infusion administration daily from Days 1 to 5 in Cycle 1 (Cycle length = 14 days) and then in Cycle 2 and subsequent cycles (each Cycle length = 21 days) until disease progression or the participant met any discontinuation criteria.	7
Part B, Dose Expansion, Melanoma: Nemvaleukin Alfa 6 mcg/kg Participants with melanoma received nemvaleukin alfa 6 mcg/kg IV infusion administration daily from Days 1 to 5 in Cycle 1 (Cycle length = 14 days) and then in Cycle 2 and subsequent cycles (each Cycle length = 21 days) until disease progression or the participant met any discontinuation criteria.	47
Part B, Dose Expansion, RCC: Nemvaleukin 6 Alfa mcg/kg Participants with RCC received nemvaleukin alfa 6 mcg/kg IV infusion administration daily from Days 1 to 5 in Cycle 1 (Cycle length = 14 days) and then in Cycle 2 and subsequent cycles (each Cycle length = 21 days) until disease progression or the participant met any discontinuation criteria.	27
Part C, Combination Therapy, Safety Run-in: Nemvaleukin Alfa 1 mcg/kg Participants with any tumor type received nemvaleukin alfa 1 mcg/kg IV infusion administration daily from Days 1 to 5 in combination with pembrolizumab 200 mg IV infusion on Day 1 in each Cycle (cycle length = 21 days) for a maximum of 2 years for as long as the Participant appeared to be deriving clinical benefit (i.e., objective response or SD) and had tolerated therapy well. Participants could continue nemvaleukin alfa as monotherapy beyond the maximum of 2 years of treatment by switching to monotherapy at the joint discretion of the Investigator and Sponsor and if they did not meet any other criteria for discontinuation.	3
Part C, Combination Therapy, Cohort 1 + Safety Run-in: Nemvaleukin Alfa 3mcg/kg +Pembrolizumab 200mg Participants with PD-1/L1 unapproved tumor types (PD-1/L1 treatment naive) received nemvaleukin alfa 3 mcg/kg IV infusion administration daily from Days 1 to 5 in combination with pembrolizumab 200 mg IV infusion on Day 1 in each Cycle (cycle length = 21 days) for a maximum of 2 years for as long as the participant appeared to be deriving clinical benefit (i.e., objective response or SD) and had tolerated therapy well. Participants could continue nemvaleukin alfa as monotherapy beyond the maximum of 2 years of treatment by switching to monotherapy at the joint discretion of the Investigator and Sponsor and if they did not meet any other criteria for discontinuation. The Safety Run-in for nemvaleukin alfa 3 mcg/kg was combined with Cohort 1 of Part C due to same dosing level and regimen.	42
Part C, Combination Therapy, Cohort 2: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg Participants with PD-1/L1 approved tumor types (PD-1/L1 treatment pretreated) received nemvaleukin alfa 3 mcg/kg IV infusion administration daily from Days 1 to 5 in combination with pembrolizumab 200 mg IV infusion on Day 1 in each Cycle (cycle length = 21 days) for a maximum of 2 years for as long as the participant appeared to be deriving clinical benefit (i.e., objective response or SD) and had tolerated therapy well. Participants could continue nemvaleukin alfa as monotherapy beyond the maximum of 2 years of treatment by switching to monotherapy at the joint discretion of the Investigator and Sponsor and if they did not meet any other criteria for discontinuation.	26
Part C, Combination Therapy, Cohort 3: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg Participants with PD-1/L1 approved tumor types (PD-1/L1 treatment naive) received nemvaleukin alfa 3 mcg/kg IV infusion administration daily from Days 1 to 5 in combination with pembrolizumab 200 mg IV infusion on Day 1 in each Cycle (cycle length = 21 days) for a maximum of 2 years for as long as the participant appeared to be deriving clinical benefit (i.e., objective response or SD) and had tolerated therapy well. Participants could continue nemvaleukin alfa as monotherapy beyond the maximum of 2 years of treatment by switching to monotherapy at the joint discretion of the Investigator and Sponsor and if they did not meet any other criteria for discontinuation.	26
Part C, Combination Therapy, Rollover, Cohort 4: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg Participants rollover from Parts A or B received nemvaleukin alfa 3 mcg/kg IV infusion administration daily from Days 1 to 5 in combination with pembrolizumab 200 mg IV infusion on Day 1 in each Cycle (cycle length = 21 days) for a maximum of 2 years for as long as the participant appeared to be deriving clinical benefit (i.e., objective response or SD) and had tolerated therapy well. Participants could continue nemvaleukin alfa as monotherapy beyond the maximum of 2 years of treatment by switching to monotherapy at the joint discretion of the Investigator and Sponsor and if they did not meet any other criteria for discontinuation.	43
Part C, Combination Therapy, Cohort 5: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg Participants with melanoma received nemvaleukin alfa 6 mcg/kg IV infusion administration daily from Days 1 to 5 in combination with pembrolizumab 200 mg IV infusion on Day 1 in each Cycle (cycle length = 21 days) for a maximum of 2 years for as long as the participant appeared to be deriving clinical benefit (i.e., objective response or SD) and had tolerated therapy well. Participants could continue nemvaleukin alfa as monotherapy beyond the maximum of 2 years of treatment by switching to monotherapy at the joint discretion of the Investigator and Sponsor and if they did not meet any other criteria for discontinuation.	3
Part C, Combination Therapy, Cohort 6: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg Participants with NSCLC received nemvaleukin alfa 6 mcg/kg IV infusion administration daily from Days 1 to 5 in combination with pembrolizumab 200 mg IV infusion on Day 1 in each Cycle (cycle length = 21 days) for a maximum of 2 years for as long as the participant appeared to be deriving clinical benefit (i.e., objective response or SD) and had tolerated therapy well. Participants could continue nemvaleukin alfa as monotherapy beyond the maximum of 2 years of treatment by switching to monotherapy at the joint discretion of the Investigator and Sponsor and if they did not meet any other criteria for discontinuation.	21
Part C, Combination Therapy, Cohort 7: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg Participants with SCCHN received nemvaleukin alfa 6 mcg/kg IV infusion administration daily from Days 1 to 5 in combination with pembrolizumab 200 mg IV infusion on Day 1 in each Cycle (cycle length = 21 days) for a maximum of 2 years for as long as the participant appeared to be deriving clinical benefit (i.e., objective response or SD) and had tolerated therapy well. Participants could continue nemvaleukin alfa as monotherapy beyond the maximum of 2 years of treatment by switching to monotherapy at the joint discretion of the Investigator and Sponsor and if they did not meet any other criteria for discontinuation.	2
Total	286

Withdrawals & dropouts

Period	Reason	FG000	FG001	FG002	FG003	FG004	FG005	FG006	FG007	FG008	FG009	FG010	FG011	FG012	FG013	FG014	FG015	FG016
Part A	Adverse Event	1	0	1	4	1	0	0	0	0	0	0	0	0	0	0	0	0
Part A	Clinical Progression	1	0	2	1	5	0	0	0	0	0	0	0	0	0	0	0	0
Part A	Death	0	0	0	0	0	0	3	0	0	0	0	0	0	0	0	0	0
Part A	Lost to Follow-up	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0
Part A	Progressive Disease	3	3	3	2	2	0	0	0	0	0	0	0	0	0	0	0	0
Part A	Protocol Deviation	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Part A	Rolled Over to Part C, Cohort 4	0	0	0	0	1	2	2	0	0	0	0	0	0	0	0	0	0
Part A	Withdrawal by Subject	0	0	0	1	3	1	1	0	0	0	0	0	0	0	0	0	0
Part B	Death	0	0	0	0	0	0	0	7	7	0	0	0	0	0	0	0	0
Part B	Progressive Disease	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
Part B	Rolled Over to Part C, Cohort 4	0	0	0	0	0	0	0	26	12	0	0	0	0	0	0	0	0
Part B	Withdrawal by Subject	0	0	0	0	0	0	0	10	7	0	0	0	0	0	0	0	0
Part C	Adverse Event	0	0	0	0	0	0	0	0	0	0	3	1	0	1	0	0	0
Part C	Clinical Progression	0	0	0	0	0	0	0	0	0	1	3	0	0	1	0	0	0
Part C	Death	0	0	0	0	0	0	0	0	0	0	7	5	6	8	1	8	1
Part C	Lost to Follow-up	0	0	0	0	0	0	0	0	0	0	1	1	1	3	0	0	0
Part C	Other	0	0	0	0	0	0	0	0	0	0	0	2	2	0	0	0	0
Part C	Physician Decision	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
Part C	Progressive Disease	0	0	0	0	0	0	0	0	0	2	13	2	0	1	0	0	0
Part C	Withdrawal by Subject	0	0	0	0	0	0	0	0	0	0	13	15	13	21	0	12	1

Baseline characteristics

Characteristic	Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Part A, Dose Escalation: Nemvaleukin Alfa 8 mcg/kg	Part A, Dose Escalation: Nemvaleukin Alfa 10 mcg/kg	Part B, Dose Expansion, Melanoma: Nemvaleukin Alfa 6 mcg/kg	Part B, Dose Expansion, RCC: Nemvaleukin 6 Alfa mcg/kg	Part C, Combination Therapy, Safety Run-in: Nemvaleukin Alfa 1 mcg/kg	Part C, Combination Therapy, Cohort 1 + Safety Run-in: Nemvaleukin Alfa 3mcg/kg +Pembrolizumab 200mg	Part C, Combination Therapy, Cohort 2: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Part C, Combination Therapy, Cohort 3: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Part C, Combination Therapy, Rollover, Cohort 4: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Part C, Combination Therapy, Cohort 5: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Part C, Combination Therapy, Cohort 6: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Part C, Combination Therapy, Cohort 7: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Total
Age, Customized Part A 18 to 64 years	3 Participants	5 Participants	4 Participants	4 Participants	3 Participants	4 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	5 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	28 Participants
Age, Customized Part A 65 to 84 years	1 Participants	2 Participants	4 Participants	8 Participants	0 Participants	3 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	18 Participants
Age, Customized Part A > 84 years	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Age, Customized Part B 18 to 64 years	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	20 Participants	10 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	30 Participants
Age, Customized Part B 65 to 84 years	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	27 Participants	17 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	44 Participants
Age, Customized Part B > 84 years	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	—	0 Participants
Age, Customized Part C 18 to 64 years	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	30 Participants	20 Participants	0 Participants	15 Participants	18 Participants	1 Participants	11 Participants	1 Participants	96 Participants
Age, Customized Part C 65 to 84 years	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	3 Participants	12 Participants	6 Participants	0 Participants	11 Participants	25 Participants	2 Participants	9 Participants	1 Participants	69 Participants
Age, Customized Part C > 84 years	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	1 Participants
Ethnicity (NIH/OMB) Part A Hispanic or Latino	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	—	—	—	—	—	1 Participants	—	—	—	—	—	2 Participants
Ethnicity (NIH/OMB) Part A Not Hispanic or Latino	4 Participants	7 Participants	8 Participants	12 Participants	3 Participants	6 Participants	—	—	—	—	—	4 Participants	—	—	—	—	—	44 Participants
Ethnicity (NIH/OMB) Part A Unknown or Not Reported	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	0 Participants	—	—	—	—	—	0 Participants
Ethnicity (NIH/OMB) Part B Hispanic or Latino	—	—	—	—	—	—	0 Participants	1 Participants	—	—	—	—	—	—	—	—	—	1 Participants
Ethnicity (NIH/OMB) Part B Not Hispanic or Latino	—	—	—	—	—	—	47 Participants	26 Participants	—	—	—	—	—	—	—	—	—	73 Participants
Ethnicity (NIH/OMB) Part B Unknown or Not Reported	—	—	—	—	—	—	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—	0 Participants
Ethnicity (NIH/OMB) Part C Hispanic or Latino	—	—	—	—	—	—	—	—	0 Participants	1 Participants	1 Participants	—	2 Participants	1 Participants	0 Participants	1 Participants	0 Participants	6 Participants
Ethnicity (NIH/OMB) Part C Not Hispanic or Latino	—	—	—	—	—	—	—	—	3 Participants	40 Participants	25 Participants	—	24 Participants	42 Participants	3 Participants	20 Participants	2 Participants	159 Participants
Ethnicity (NIH/OMB) Part C Unknown or Not Reported	—	—	—	—	—	—	—	—	0 Participants	1 Participants	0 Participants	—	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants
Race (NIH/OMB) Part A American Indian or Alaska Native	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	0 Participants	—	—	—	—	—	0 Participants
Race (NIH/OMB) Part A Asian	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	0 Participants	—	—	—	—	—	0 Participants
Race (NIH/OMB) Part A Black or African American	0 Participants	1 Participants	0 Participants	2 Participants	1 Participants	0 Participants	—	—	—	—	—	0 Participants	—	—	—	—	—	4 Participants
Race (NIH/OMB) Part A More than one race	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	0 Participants	—	—	—	—	—	0 Participants
Race (NIH/OMB) Part A Native Hawaiian or Other Pacific Islander	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	0 Participants	—	—	—	—	—	0 Participants
Race (NIH/OMB) Part A Unknown or Not Reported	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	—	—	—	—	—	0 Participants	—	—	—	—	—	1 Participants
Race (NIH/OMB) Part A White	4 Participants	6 Participants	8 Participants	10 Participants	2 Participants	6 Participants	—	—	—	—	—	5 Participants	—	—	—	—	—	41 Participants
Race (NIH/OMB) Part B American Indian or Alaska Native	—	—	—	—	—	—	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—	0 Participants
Race (NIH/OMB) Part B Asian	—	—	—	—	—	—	5 Participants	1 Participants	—	—	—	—	—	—	—	—	—	6 Participants
Race (NIH/OMB) Part B Black or African American	—	—	—	—	—	—	0 Participants	1 Participants	—	—	—	—	—	—	—	—	—	1 Participants
Race (NIH/OMB) Part B More than one race	—	—	—	—	—	—	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—	0 Participants
Race (NIH/OMB) Part B Native Hawaiian or Other Pacific Islander	—	—	—	—	—	—	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—	0 Participants
Race (NIH/OMB) Part B Unknown or Not Reported	—	—	—	—	—	—	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—	0 Participants
Race (NIH/OMB) Part B White	—	—	—	—	—	—	42 Participants	25 Participants	—	—	—	—	—	—	—	—	—	67 Participants
Race (NIH/OMB) Part C American Indian or Alaska Native	—	—	—	—	—	—	—	—	0 Participants	0 Participants	0 Participants	—	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Part C Asian	—	—	—	—	—	—	—	—	0 Participants	0 Participants	1 Participants	—	0 Participants	1 Participants	0 Participants	1 Participants	0 Participants	3 Participants
Race (NIH/OMB) Part C Black or African American	—	—	—	—	—	—	—	—	0 Participants	7 Participants	3 Participants	—	3 Participants	1 Participants	0 Participants	1 Participants	0 Participants	15 Participants
Race (NIH/OMB) Part C More than one race	—	—	—	—	—	—	—	—	0 Participants	0 Participants	0 Participants	—	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Part C Native Hawaiian or Other Pacific Islander	—	—	—	—	—	—	—	—	0 Participants	0 Participants	0 Participants	—	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Part C Unknown or Not Reported	—	—	—	—	—	—	—	—	0 Participants	1 Participants	2 Participants	—	1 Participants	1 Participants	0 Participants	1 Participants	0 Participants	6 Participants
Race (NIH/OMB) Part C White	—	—	—	—	—	—	—	—	3 Participants	34 Participants	20 Participants	—	22 Participants	40 Participants	3 Participants	18 Participants	2 Participants	142 Participants
Sex: Female, Male Part A Female	1 Participants	0 Participants	4 Participants	7 Participants	2 Participants	4 Participants	—	—	—	—	—	1 Participants	—	—	—	—	—	19 Participants
Sex: Female, Male Part A Male	3 Participants	7 Participants	4 Participants	5 Participants	1 Participants	3 Participants	—	—	—	—	—	4 Participants	—	—	—	—	—	27 Participants
Sex: Female, Male Part B Female	—	—	—	—	—	—	22 Participants	3 Participants	—	—	—	—	—	—	—	—	—	25 Participants
Sex: Female, Male Part B Male	—	—	—	—	—	—	25 Participants	24 Participants	—	—	—	—	—	—	—	—	—	49 Participants
Sex: Female, Male Part C Female	—	—	—	—	—	—	—	—	1 Participants	28 Participants	12 Participants	—	13 Participants	18 Participants	1 Participants	7 Participants	1 Participants	81 Participants
Sex: Female, Male Part C Male	—	—	—	—	—	—	—	—	2 Participants	14 Participants	14 Participants	—	13 Participants	25 Participants	2 Participants	14 Participants	1 Participants	85 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk	EG003 affected / at risk	EG004 affected / at risk	EG005 affected / at risk	EG006 affected / at risk	EG007 affected / at risk	EG008 affected / at risk	EG009 affected / at risk	EG010 affected / at risk	EG011 affected / at risk	EG012 affected / at risk	EG013 affected / at risk	EG014 affected / at risk	EG015 affected / at risk	EG016 affected / at risk
deaths Total, all-cause mortality	0 / 5	0 / 4	0 / 7	0 / 8	1 / 12	0 / 3	3 / 7	7 / 47	7 / 27	0 / 3	7 / 42	7 / 26	8 / 26	8 / 43	1 / 3	8 / 21	1 / 2
other Total, other adverse events	5 / 5	4 / 4	7 / 7	8 / 8	12 / 12	3 / 3	7 / 7	46 / 47	27 / 27	3 / 3	42 / 42	26 / 26	25 / 26	38 / 43	3 / 3	21 / 21	2 / 2
serious Total, serious adverse events	2 / 5	0 / 4	2 / 7	3 / 8	5 / 12	0 / 3	5 / 7	11 / 47	12 / 27	0 / 3	19 / 42	10 / 26	11 / 26	14 / 43	2 / 3	12 / 21	2 / 2

Outcome results

Primary

Part A: Number of Participants With Dose-limiting Toxicities (DLTs) Based on Common Terminology Criteria for Adverse Events (CTCAE)

DLT was defined by any of following events possibly, probably, or definitely related to ALKS 4230: Grade 4 neutrophil count decreased (neutropenia); Febrile neutropenia; CTCAE Grade 4 thrombocytopenia; Thrombocytopenia; Any Grade 3 cardiac or central nervous system toxicity; Liver transaminase elevation higher than 8\*upper limit of normal (ULN) or total bilirubin higher than 6\*ULN; Grade 4 hypoalbuminemia; Fever more than (\>) 40 degree Celsius (°C) sustained for \>24 hours; Hypotension required the use of pressors or prolonged hospitalization (\>48 hours) for hypotension requiring medical intervention; Grade 3 or higher electrolyte abnormalities; Increase in amylase or lipase; Grade 3 or higher nausea, vomiting, or diarrhea; Any other Grade 4 nonhematologic toxicity or any other Grade 3 non-hematologic toxicity; Any other toxicity or adverse event (AE) not defined above that resulted in participant removal from the study or discontinuation of dosing by the Investigator.

Time frame: Cycle 1 Day 1 through Cycle 2 Day 15 (Cycle 1 length = 14 days; Cycle 2 length= 21 days)

Population: Safety population included all participants who received at least 1 dose of nemvaleukin alfa or pembrolizumab.

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Part A: Number of Participants With Dose-limiting Toxicities (DLTs) Based on Common Terminology Criteria for Adverse Events (CTCAE)	0 Participants
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Part A: Number of Participants With Dose-limiting Toxicities (DLTs) Based on Common Terminology Criteria for Adverse Events (CTCAE)	0 Participants
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Part A: Number of Participants With Dose-limiting Toxicities (DLTs) Based on Common Terminology Criteria for Adverse Events (CTCAE)	0 Participants
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Part A: Number of Participants With Dose-limiting Toxicities (DLTs) Based on Common Terminology Criteria for Adverse Events (CTCAE)	2 Participants
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Part A: Number of Participants With Dose-limiting Toxicities (DLTs) Based on Common Terminology Criteria for Adverse Events (CTCAE)	3 Participants
Part A, Dose Escalation: Nemvaleukin Alfa 8 mcg/kg	Part A: Number of Participants With Dose-limiting Toxicities (DLTs) Based on Common Terminology Criteria for Adverse Events (CTCAE)	0 Participants
Part A, Dose Escalation: Nemvaleukin Alfa 10 mcg/kg	Part A: Number of Participants With Dose-limiting Toxicities (DLTs) Based on Common Terminology Criteria for Adverse Events (CTCAE)	1 Participants

Primary

Parts A, B, and C: Number of Participants With TEAEs by Severity Grading

TEAEs were defined as AEs that were newly occurring or worsening from the time of the first dose of study drug. Severity was graded according to the National Cancer Institute (NCI) CTCAE (version 4.03) where, Grade 1: Mild- asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2: Moderate- minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL) Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL. Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death related to AE. As planned, Grades 1 and 2 were combined for reporting.

Time frame: From first dose of study drug until 30 days after last dose (up to 10 months for Part A; up to 41.3 months for Part B; up to 51.5 months for Part C)

Population: Safety population included all participants who received at least 1 dose of nemvaleukin alfa or pembrolizumab.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	Participants With Grade 4 TEAEs	0 Participants
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	Participants With Grade 3 TEAEs	3 Participants
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	Participants With Grade 5 TEAEs	0 Participants
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	Participants With Grade 1 and 2 TEAEs	2 Participants
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	Participants With Grade 3 TEAEs	1 Participants
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	Participants With Grade 4 TEAEs	0 Participants
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	Participants With Grade 1 and 2 TEAEs	3 Participants
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	Participants With Grade 5 TEAEs	0 Participants
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	Participants With Grade 4 TEAEs	0 Participants
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	Participants With Grade 5 TEAEs	0 Participants
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	Participants With Grade 3 TEAEs	3 Participants
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	Participants With Grade 1 and 2 TEAEs	4 Participants
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	Participants With Grade 3 TEAEs	6 Participants
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	Participants With Grade 4 TEAEs	0 Participants
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	Participants With Grade 1 and 2 TEAEs	2 Participants
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	Participants With Grade 5 TEAEs	0 Participants
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	Participants With Grade 1 and 2 TEAEs	3 Participants
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	Participants With Grade 3 TEAEs	8 Participants
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	Participants With Grade 5 TEAEs	1 Participants
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	Participants With Grade 4 TEAEs	0 Participants
Part A, Dose Escalation: Nemvaleukin Alfa 8 mcg/kg	Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	Participants With Grade 5 TEAEs	0 Participants
Part A, Dose Escalation: Nemvaleukin Alfa 8 mcg/kg	Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	Participants With Grade 4 TEAEs	0 Participants
Part A, Dose Escalation: Nemvaleukin Alfa 8 mcg/kg	Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	Participants With Grade 1 and 2 TEAEs	1 Participants
Part A, Dose Escalation: Nemvaleukin Alfa 8 mcg/kg	Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	Participants With Grade 3 TEAEs	2 Participants
Part A, Dose Escalation: Nemvaleukin Alfa 10 mcg/kg	Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	Participants With Grade 5 TEAEs	1 Participants
Part A, Dose Escalation: Nemvaleukin Alfa 10 mcg/kg	Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	Participants With Grade 3 TEAEs	3 Participants
Part A, Dose Escalation: Nemvaleukin Alfa 10 mcg/kg	Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	Participants With Grade 1 and 2 TEAEs	1 Participants
Part A, Dose Escalation: Nemvaleukin Alfa 10 mcg/kg	Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	Participants With Grade 4 TEAEs	2 Participants
Part B, Dose Expansion, Melanoma: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	Participants With Grade 3 TEAEs	28 Participants
Part B, Dose Expansion, Melanoma: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	Participants With Grade 1 and 2 TEAEs	6 Participants
Part B, Dose Expansion, Melanoma: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	Participants With Grade 5 TEAEs	0 Participants
Part B, Dose Expansion, Melanoma: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	Participants With Grade 4 TEAEs	12 Participants
Part B, Dose Expansion, RCC: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	Participants With Grade 5 TEAEs	1 Participants
Part B, Dose Expansion, RCC: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	Participants With Grade 1 and 2 TEAEs	5 Participants
Part B, Dose Expansion, RCC: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	Participants With Grade 3 TEAEs	16 Participants
Part B, Dose Expansion, RCC: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	Participants With Grade 4 TEAEs	5 Participants
Part C, Combination Therapy, Safety Run-in: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	Participants With Grade 4 TEAEs	0 Participants
Part C, Combination Therapy, Safety Run-in: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	Participants With Grade 1 and 2 TEAEs	3 Participants
Part C, Combination Therapy, Safety Run-in: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	Participants With Grade 5 TEAEs	0 Participants
Part C, Combination Therapy, Safety Run-in: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	Participants With Grade 3 TEAEs	0 Participants
Part C, Combination Therapy, Cohort 1 +Safety Run-in: Nemvaleukin Alfa 3 mcg/kg+Pembrolizumab 200 mg	Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	Participants With Grade 4 TEAEs	4 Participants
Part C, Combination Therapy, Cohort 1 +Safety Run-in: Nemvaleukin Alfa 3 mcg/kg+Pembrolizumab 200 mg	Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	Participants With Grade 5 TEAEs	3 Participants
Part C, Combination Therapy, Cohort 1 +Safety Run-in: Nemvaleukin Alfa 3 mcg/kg+Pembrolizumab 200 mg	Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	Participants With Grade 3 TEAEs	19 Participants
Part C, Combination Therapy, Cohort 1 +Safety Run-in: Nemvaleukin Alfa 3 mcg/kg+Pembrolizumab 200 mg	Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	Participants With Grade 1 and 2 TEAEs	16 Participants
Part C, Combination Therapy, Cohort 2: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	Participants With Grade 4 TEAEs	5 Participants
Part C, Combination Therapy, Cohort 2: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	Participants With Grade 1 and 2 TEAEs	7 Participants
Part C, Combination Therapy, Cohort 2: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	Participants With Grade 5 TEAEs	0 Participants
Part C, Combination Therapy, Cohort 2: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	Participants With Grade 3 TEAEs	14 Participants
Part C, Combination Therapy, Cohort 3: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	Participants With Grade 1 and 2 TEAEs	6 Participants
Part C, Combination Therapy, Cohort 3: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	Participants With Grade 4 TEAEs	5 Participants
Part C, Combination Therapy, Cohort 3: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	Participants With Grade 5 TEAEs	0 Participants
Part C, Combination Therapy, Cohort 3: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	Participants With Grade 3 TEAEs	15 Participants
Part C, Combination Therapy, Rollover, Cohort 4: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	Participants With Grade 3 TEAEs	21 Participants
Part C, Combination Therapy, Rollover, Cohort 4: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	Participants With Grade 4 TEAEs	4 Participants
Part C, Combination Therapy, Rollover, Cohort 4: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	Participants With Grade 5 TEAEs	1 Participants
Part C, Combination Therapy, Rollover, Cohort 4: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	Participants With Grade 1 and 2 TEAEs	13 Participants
Part C, Combination Therapy, Cohort 5: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	Participants With Grade 5 TEAEs	0 Participants
Part C, Combination Therapy, Cohort 5: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	Participants With Grade 4 TEAEs	1 Participants
Part C, Combination Therapy, Cohort 5: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	Participants With Grade 3 TEAEs	1 Participants
Part C, Combination Therapy, Cohort 5: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	Participants With Grade 1 and 2 TEAEs	1 Participants
Part C, Combination Therapy, Cohort 6: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	Participants With Grade 5 TEAEs	0 Participants
Part C, Combination Therapy, Cohort 6: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	Participants With Grade 1 and 2 TEAEs	4 Participants
Part C, Combination Therapy, Cohort 6: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	Participants With Grade 4 TEAEs	1 Participants
Part C, Combination Therapy, Cohort 6: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	Participants With Grade 3 TEAEs	16 Participants
Part C, Combination Therapy, Cohort 7: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	Participants With Grade 3 TEAEs	1 Participants
Part C, Combination Therapy, Cohort 7: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	Participants With Grade 5 TEAEs	0 Participants
Part C, Combination Therapy, Cohort 7: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	Participants With Grade 4 TEAEs	1 Participants
Part C, Combination Therapy, Cohort 7: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Number of Participants With TEAEs by Severity Grading	Participants With Grade 1 and 2 TEAEs	0 Participants

Primary

Parts A, B, and C: Number of Participants With Treatment-emergent Adverse Events (TEAEs)

TEAEs were defined as AEs that were newly occurring or worsening from the time of the first dose of study drug. An AE was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product.

Time frame: From first dose of study drug until 30 days after last dose (up to 10 months for Part A; up to 41.3 months for Part B; up to 51.5 months for Part C)

Population: Safety population included all participants who received at least 1 dose of nemvaleukin alfa or pembrolizumab.

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Parts A, B, and C: Number of Participants With Treatment-emergent Adverse Events (TEAEs)	5 Participants
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Parts A, B, and C: Number of Participants With Treatment-emergent Adverse Events (TEAEs)	4 Participants
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Number of Participants With Treatment-emergent Adverse Events (TEAEs)	7 Participants
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Parts A, B, and C: Number of Participants With Treatment-emergent Adverse Events (TEAEs)	8 Participants
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Number of Participants With Treatment-emergent Adverse Events (TEAEs)	12 Participants
Part A, Dose Escalation: Nemvaleukin Alfa 8 mcg/kg	Parts A, B, and C: Number of Participants With Treatment-emergent Adverse Events (TEAEs)	3 Participants
Part A, Dose Escalation: Nemvaleukin Alfa 10 mcg/kg	Parts A, B, and C: Number of Participants With Treatment-emergent Adverse Events (TEAEs)	7 Participants
Part B, Dose Expansion, Melanoma: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Number of Participants With Treatment-emergent Adverse Events (TEAEs)	46 Participants
Part B, Dose Expansion, RCC: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Number of Participants With Treatment-emergent Adverse Events (TEAEs)	27 Participants
Part C, Combination Therapy, Safety Run-in: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Number of Participants With Treatment-emergent Adverse Events (TEAEs)	3 Participants
Part C, Combination Therapy, Cohort 1 +Safety Run-in: Nemvaleukin Alfa 3 mcg/kg+Pembrolizumab 200 mg	Parts A, B, and C: Number of Participants With Treatment-emergent Adverse Events (TEAEs)	42 Participants
Part C, Combination Therapy, Cohort 2: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Number of Participants With Treatment-emergent Adverse Events (TEAEs)	26 Participants
Part C, Combination Therapy, Cohort 3: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Number of Participants With Treatment-emergent Adverse Events (TEAEs)	26 Participants
Part C, Combination Therapy, Rollover, Cohort 4: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Number of Participants With Treatment-emergent Adverse Events (TEAEs)	39 Participants
Part C, Combination Therapy, Cohort 5: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Number of Participants With Treatment-emergent Adverse Events (TEAEs)	3 Participants
Part C, Combination Therapy, Cohort 6: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Number of Participants With Treatment-emergent Adverse Events (TEAEs)	21 Participants
Part C, Combination Therapy, Cohort 7: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Number of Participants With Treatment-emergent Adverse Events (TEAEs)	2 Participants

Primary

Parts B and C: Overall Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1

ORR rate was defined as the percentage of participants with objective evidence of CR or PR based on RECIST v1.1. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeters (mm). Partial Response (PR): At least a 30 percent (%) decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame: From first dose of study drug up to 40.3 months for Part B and up to 50.5 months for Part C

Population: The antitumor evaluable population consisted of participants who complete 2 cycles of therapy and had at least one follow-up scan.

Arm	Measure	Value (NUMBER)
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Parts B and C: Overall Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1	8.7 percentage of participants
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Parts B and C: Overall Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1	13.6 percentage of participants
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Parts B and C: Overall Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1	0.0 percentage of participants
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Parts B and C: Overall Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1	13.9 percentage of participants
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Parts B and C: Overall Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1	0.0 percentage of participants
Part A, Dose Escalation: Nemvaleukin Alfa 8 mcg/kg	Parts B and C: Overall Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1	28.6 percentage of participants
Part A, Dose Escalation: Nemvaleukin Alfa 10 mcg/kg	Parts B and C: Overall Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1	7.7 percentage of participants
Part B, Dose Expansion, Melanoma: Nemvaleukin Alfa 6 mcg/kg	Parts B and C: Overall Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1	66.7 percentage of participants
Part B, Dose Expansion, RCC: Nemvaleukin Alfa 6 mcg/kg	Parts B and C: Overall Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1	11.1 percentage of participants
Part C, Combination Therapy, Safety Run-in: Nemvaleukin Alfa 1 mcg/kg	Parts B and C: Overall Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1	50.0 percentage of participants

Secondary

Part B and Part C Cohorts C5, C6, C7: Durable Response Rate (DRR) Based on RECIST v.1.1

DRR was defined as the percentage of participants with an objective response (complete or partial response per RECIST 1.1) lasting continuously for 6 months and starting any time within 12 months of initiating the study drug.

Time frame: From first dose of study drug up to 40.3 months for Part B; up to 50.5 months for Part C

Population: As pre-specified in statistical analysis plan, this outcome measure of DRR was not summarized and hence, no data was reported in this outcome measure.

Secondary

Part B and Part C Cohorts C5, C6, C7: Immune DRR (iDRR) Based on iRECIST

iDRR was defined as the percentage of participants with an objective response (complete or partial response per iRECIST) lasting continuously for 6 months and starting any time within 12 months of initiating the study drug.

Time frame: From first dose of study drug up to 40.3 months for Part B; up to 50.5 months for Part C

Population: No data collection or analysis based on irRC and iRECIST was performed as iRECIST was implemented during the middle of the study conduct to replace irRC. However, no data was collected and analyzed for iRECIST either. Therefore, no data is available to report for this outcome measure.

Secondary

Part B and Part C Cohorts C5, C6, C7: Immune PFS (iPFS)

iPFS was defined as the time from the first dose of study medication to the first documentation of objective tumor progression based on iRECIST (immune confirmed progressive disease \[iCPD\]) or death due to any cause.

Time frame: From first dose of study drug up to 40.3 months for Part B; up to 50.5 months for Part C

Secondary

Part B and Part C Cohorts C5, C6, C7: Progression-free Survival (PFS) Based on RECIST v.1.1

Progression-free survival was defined as the time from the first dose of nemvaleukin to the first documentation of objective tumor progression or death due to any cause. PD: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

Time frame: From first dose of study drug up to the first documentation of objective tumor progression or death due to any cause (up to 40.3 months for Part B and up to 50.5 months for Part C)

Population: The antitumor evaluable population consisted of participants who complete 2 cycles of therapy and had at least one follow-up scan.

Arm	Measure	Value (MEDIAN)
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Part B and Part C Cohorts C5, C6, C7: Progression-free Survival (PFS) Based on RECIST v.1.1	16.14 weeks
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Part B and Part C Cohorts C5, C6, C7: Progression-free Survival (PFS) Based on RECIST v.1.1	12.43 weeks
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Part B and Part C Cohorts C5, C6, C7: Progression-free Survival (PFS) Based on RECIST v.1.1	NA weeks
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Part B and Part C Cohorts C5, C6, C7: Progression-free Survival (PFS) Based on RECIST v.1.1	18.64 weeks
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Part B and Part C Cohorts C5, C6, C7: Progression-free Survival (PFS) Based on RECIST v.1.1	35.57 weeks

Secondary

Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa

Cycle 1 length = 14 days for Part A and 21 days for Part B and C; Cycle 2 length= 21 days for all parts.

Time frame: Cycle 1 and 2 Day 1: 0, 0.5, 1, 2, 4, 8, 16, and 24 hours post-dose; Cycle 1 Day 5: 0, 0.5, 1, 2, 4, 8, 16, 24, and 72 hours post-dose; Cycle 2 Day 5: 0, 0.5, 1, 2, 4, 8, 16, 24, 72, and 240 hours post-dose

Population: The PK population consisted of all participants who received at least 1 dose of nemvaleukin alfa and had at least 1 measurable serum concentration of nemvaleukin alfa at any scheduled PK time point. Here, overall number of participants analyzed signifies participants who were evaluable for this outcome measure and number analyzed signifies participants who were evaluable at specified timepoints.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)	Dispersion
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 2 Day 1	2.47 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 32.4
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 1 Day 5	2.52 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 17.3
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 2 Day 5	2.61 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 16.6
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 1 Day 1	2.96 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 53.1
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 2 Day 1	15.3 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 45.4
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 1 Day 1	17.0 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 35.6
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 1 Day 5	14.4 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 23.6
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 2 Day 5	11.5 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 18.4
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 1 Day 5	48.2 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 55.9
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 2 Day 1	69.2 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 50.3
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 1 Day 1	66.5 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 36.5
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 2 Day 5	40.8 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 21.2
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 1 Day 1	195 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 252.1
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 2 Day 5	167 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 51.5
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 1 Day 5	106 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 205.5
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 2 Day 1	274 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 39
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 2 Day 5	361 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 50.4
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 2 Day 1	478 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 30.7
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 1 Day 1	557 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 28.7
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 1 Day 5	379 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 46
Part A, Dose Escalation: Nemvaleukin Alfa 8 mcg/kg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 1 Day 5	323 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 84.1
Part A, Dose Escalation: Nemvaleukin Alfa 8 mcg/kg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 1 Day 1	616 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 42.3
Part A, Dose Escalation: Nemvaleukin Alfa 8 mcg/kg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 2 Day 1	512 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 35.6
Part A, Dose Escalation: Nemvaleukin Alfa 8 mcg/kg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 2 Day 5	439 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 3.5
Part A, Dose Escalation: Nemvaleukin Alfa 10 mcg/kg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 2 Day 5	312 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 131
Part A, Dose Escalation: Nemvaleukin Alfa 10 mcg/kg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 1 Day 5	346 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 47.8
Part A, Dose Escalation: Nemvaleukin Alfa 10 mcg/kg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 2 Day 1	573 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 36.8
Part A, Dose Escalation: Nemvaleukin Alfa 10 mcg/kg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 1 Day 1	719 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 39.7
Part B, Dose Expansion, Melanoma: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 1 Day 1	608 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 30.1
Part B, Dose Expansion, Melanoma: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 2 Day 1	517 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 44.5
Part B, Dose Expansion, Melanoma: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 2 Day 5	287 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 60.9
Part B, Dose Expansion, Melanoma: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 1 Day 5	292 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 61.4
Part B, Dose Expansion, RCC: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 1 Day 5	312 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 40.6
Part B, Dose Expansion, RCC: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 1 Day 1	723 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 23.2
Part B, Dose Expansion, RCC: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 2 Day 1	594 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 25.9
Part B, Dose Expansion, RCC: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 2 Day 5	329 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 45.3
Part C, Combination Therapy, Safety Run-in: Nemvaleukin Alfa 1 mcg/kg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 2 Day 1	56.1 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 12.9
Part C, Combination Therapy, Safety Run-in: Nemvaleukin Alfa 1 mcg/kg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 1 Day 1	84.1 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 39.5
Part C, Combination Therapy, Safety Run-in: Nemvaleukin Alfa 1 mcg/kg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 1 Day 5	56.7 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 18.8
Part C, Combination Therapy, Safety Run-in: Nemvaleukin Alfa 1 mcg/kg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 2 Day 5	52.0 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 18.5
Part C, Combination Therapy, Cohort 1 +Safety Run-in: Nemvaleukin Alfa 3 mcg/kg+Pembrolizumab 200 mg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 1 Day 1	248 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 23.4
Part C, Combination Therapy, Cohort 1 +Safety Run-in: Nemvaleukin Alfa 3 mcg/kg+Pembrolizumab 200 mg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 1 Day 5	121 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 68.5
Part C, Combination Therapy, Cohort 1 +Safety Run-in: Nemvaleukin Alfa 3 mcg/kg+Pembrolizumab 200 mg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 2 Day 1	195 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 50.1
Part C, Combination Therapy, Cohort 1 +Safety Run-in: Nemvaleukin Alfa 3 mcg/kg+Pembrolizumab 200 mg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 2 Day 5	120 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 72.3
Part C, Combination Therapy, Cohort 2: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 1 Day 5	143 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 26.2
Part C, Combination Therapy, Cohort 2: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 1 Day 1	286 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 22.1
Part C, Combination Therapy, Cohort 2: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 2 Day 1	235 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 30.8
Part C, Combination Therapy, Cohort 2: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 2 Day 5	135 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 54.3
Part C, Combination Therapy, Cohort 3: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 2 Day 1	243 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 41.5
Part C, Combination Therapy, Cohort 3: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 1 Day 5	158 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 41.6
Part C, Combination Therapy, Cohort 3: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 1 Day 1	296 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 35
Part C, Combination Therapy, Cohort 3: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 2 Day 5	134 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 35.4
Part C, Combination Therapy, Rollover, Cohort 4: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 2 Day 5	128 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 36.6
Part C, Combination Therapy, Rollover, Cohort 4: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 1 Day 5	130 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 40.5
Part C, Combination Therapy, Rollover, Cohort 4: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 2 Day 1	212 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 39.6
Part C, Combination Therapy, Rollover, Cohort 4: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 1 Day 1	276 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 31.4
Part C, Combination Therapy, Cohort 5: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 1 Day 5	139 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 53.4
Part C, Combination Therapy, Cohort 5: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 1 Day 1	222 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 77.2
Part C, Combination Therapy, Cohort 5: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 2 Day 1	224 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 85
Part C, Combination Therapy, Cohort 5: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 2 Day 5	153 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 73.4
Part C, Combination Therapy, Cohort 6: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 2 Day 5	275 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 15
Part C, Combination Therapy, Cohort 6: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 1 Day 1	698 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 21.7
Part C, Combination Therapy, Cohort 6: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 1 Day 5	343 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 6.8
Part C, Combination Therapy, Cohort 6: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 2 Day 1	625 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 12.5
Part C, Combination Therapy, Cohort 7: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 1 Day 5	368 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 56.7
Part C, Combination Therapy, Cohort 7: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 2 Day 1	562 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 33.5
Part C, Combination Therapy, Cohort 7: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 1 Day 1	715 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 37.6
Part C, Combination Therapy, Cohort 7: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 2 Day 5	346 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 43.9
Part C, Combination Therapy, Cohort 7: Nemvaleukin 6 Alfa mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 1 Day 1	543 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 25
Part C, Combination Therapy, Cohort 7: Nemvaleukin 6 Alfa mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 2 Day 1	590 hournanogram per milliliter (hng/mL)	—
Part C, Combination Therapy, Cohort 7: Nemvaleukin 6 Alfa mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 1 Day 5	393 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 45.8
Part C, Combination Therapy, Cohort 7: Nemvaleukin 6 Alfa mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa	Cycle 2 Day 5	413 hournanogram per milliliter (hng/mL)	Geometric Coefficient of Variation 57.6

Secondary

Parts A, B, and C: Disease Control Rate (DCR) Based on RECIST v.1.1

Disease control rate was defined as the percentage of participants with objective evidence of CR, PR, or SD based on RECIST v.1.1. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

Time frame: From first dose of study drug up to 9 months for Part A; up to 40.3 months for Part B; up to 50.5 months for Part C

Population: The antitumor evaluable population consisted of participants who complete 2 cycles of therapy and had at least one follow-up scan.

Arm	Measure	Value (NUMBER)
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Parts A, B, and C: Disease Control Rate (DCR) Based on RECIST v.1.1	0.0 percentage of participants
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Parts A, B, and C: Disease Control Rate (DCR) Based on RECIST v.1.1	25.0 percentage of participants
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Disease Control Rate (DCR) Based on RECIST v.1.1	20.0 percentage of participants
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Parts A, B, and C: Disease Control Rate (DCR) Based on RECIST v.1.1	60.0 percentage of participants
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Disease Control Rate (DCR) Based on RECIST v.1.1	33.3 percentage of participants
Part A, Dose Escalation: Nemvaleukin Alfa 8 mcg/kg	Parts A, B, and C: Disease Control Rate (DCR) Based on RECIST v.1.1	33.3 percentage of participants
Part A, Dose Escalation: Nemvaleukin Alfa 10 mcg/kg	Parts A, B, and C: Disease Control Rate (DCR) Based on RECIST v.1.1	25.0 percentage of participants
Part B, Dose Expansion, Melanoma: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Disease Control Rate (DCR) Based on RECIST v.1.1	47.8 percentage of participants
Part B, Dose Expansion, RCC: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Disease Control Rate (DCR) Based on RECIST v.1.1	50.0 percentage of participants
Part C, Combination Therapy, Safety Run-in: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Disease Control Rate (DCR) Based on RECIST v.1.1	0.0 percentage of participants
Part C, Combination Therapy, Cohort 1 +Safety Run-in: Nemvaleukin Alfa 3 mcg/kg+Pembrolizumab 200 mg	Parts A, B, and C: Disease Control Rate (DCR) Based on RECIST v.1.1	30.6 percentage of participants
Part C, Combination Therapy, Cohort 2: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Disease Control Rate (DCR) Based on RECIST v.1.1	22.7 percentage of participants
Part C, Combination Therapy, Cohort 3: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Disease Control Rate (DCR) Based on RECIST v.1.1	47.6 percentage of participants
Part C, Combination Therapy, Rollover, Cohort 4: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Disease Control Rate (DCR) Based on RECIST v.1.1	46.2 percentage of participants
Part C, Combination Therapy, Cohort 5: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Disease Control Rate (DCR) Based on RECIST v.1.1	66.7 percentage of participants
Part C, Combination Therapy, Cohort 6: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Disease Control Rate (DCR) Based on RECIST v.1.1	50.0 percentage of participants
Part C, Combination Therapy, Cohort 7: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Disease Control Rate (DCR) Based on RECIST v.1.1	100 percentage of participants

Secondary

Parts A, B, and C: Immune DCR (iDCR) Based on iRECIST v1.1

iDCR was defined as the percentage of participants with objective evidence of iCR, iPR (where iCR or iPR required confirmation), or immune stable disease (iSD) (where the iSD requires to occur at Cycle 4 or later).

Time frame: From first dose of study drug up to 9 months for Part A; up to 40.3 months for Part B; up to 50.5 months for Part C

Secondary

Parts A, B, and C: Immune ORR (iORR) Based on Immune RECIST (iRECIST)

iORR was defined as the percentage of participants with objective evidence of immune CR (iCR) or immune PR (iPR) based on iRECIST guidelines.

Time frame: From first dose of study drug up to 9 months for Part A; up to 40.3 months for Part B; up to 50.5 months for Part C

Population: No data collection or analysis based on immune-related response criteria (irRC) and iRECIST was performed as iRECIST was implemented during the middle of the study conduct to replace irRC. However, no data was collected and analyzed for iRECIST either. Therefore, no data is available to report for this outcome measure.

Secondary

Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)

Time frame: Cycle 1 Days 1 and 5; Cycle 2 Days 1 and 5 (Cycle 1 length = 14 days for Part A and 21 days for Part B and C; Cycle 2 length= 21 days for all parts)

Population: The PD population consisted of all participants who received at least 1 dose of nemvaleukin alfa and had at least one available postbaseline PD measurement. Here, overall number of participants analyzed signifies participants who were evaluable for this outcome measure and number analyzed signifies participants who were evaluable at specified timepoints.

Arm	Measure	Group	Value (MEAN)	Dispersion
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 1 Day 1	104 nanogram per liter (ng/L)	Standard Deviation 61.8
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	INF-γ: Cycle 1 Day 1	23.0 nanogram per liter (ng/L)	Standard Deviation 10.3
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	INF-γ: Cycle 2 Day 1	28.0 nanogram per liter (ng/L)	Standard Deviation 24.1
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	INF-γ: Cycle 2 Day 5	31.2 nanogram per liter (ng/L)	Standard Deviation 19.2
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	INF-γ: Cycle 1 Day 5	24.7 nanogram per liter (ng/L)	Standard Deviation 10.8
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 1 Day 5	116 nanogram per liter (ng/L)	Standard Deviation 121
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 2 Day 1	41.9 nanogram per liter (ng/L)	Standard Deviation 14.7
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 2 Day 5	56.2 nanogram per liter (ng/L)	Standard Deviation 19.1
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	INF-γ: Cycle 2 Day 1	18.3 nanogram per liter (ng/L)	Standard Deviation 3.7
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 1 Day 1	118 nanogram per liter (ng/L)	Standard Deviation 33
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 2 Day 5	95.2 nanogram per liter (ng/L)	Standard Deviation 45.3
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 2 Day 1	106 nanogram per liter (ng/L)	Standard Deviation 76.4
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	INF-γ: Cycle 1 Day 5	29.1 nanogram per liter (ng/L)	Standard Deviation 10.7
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 1 Day 5	113 nanogram per liter (ng/L)	Standard Deviation 51.9
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	INF-γ: Cycle 2 Day 5	24.3 nanogram per liter (ng/L)	Standard Deviation 10.8
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	INF-γ: Cycle 1 Day 1	19.8 nanogram per liter (ng/L)	Standard Deviation 10.4
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	INF-γ: Cycle 2 Day 5	16.3 nanogram per liter (ng/L)	Standard Deviation 8.03
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 1 Day 1	169 nanogram per liter (ng/L)	Standard Deviation 280
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	INF-γ: Cycle 2 Day 1	12.2 nanogram per liter (ng/L)	Standard Deviation 4.56
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 2 Day 1	191 nanogram per liter (ng/L)	Standard Deviation 240
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	INF-γ: Cycle 1 Day 1	14.9 nanogram per liter (ng/L)	Standard Deviation 6.1
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 2 Day 5	125 nanogram per liter (ng/L)	Standard Deviation 89.3
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 1 Day 5	223 nanogram per liter (ng/L)	Standard Deviation 229
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	INF-γ: Cycle 1 Day 5	13.8 nanogram per liter (ng/L)	Standard Deviation 7.71
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	INF-γ: Cycle 1 Day 1	31.3 nanogram per liter (ng/L)	Standard Deviation 12.7
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 1 Day 5	2022 nanogram per liter (ng/L)	Standard Deviation 1491
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	INF-γ: Cycle 1 Day 5	173 nanogram per liter (ng/L)	Standard Deviation 199
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 2 Day 1	883 nanogram per liter (ng/L)	Standard Deviation 570
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	INF-γ: Cycle 2 Day 5	53.2 nanogram per liter (ng/L)	Standard Deviation 15.3
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	INF-γ: Cycle 2 Day 1	43.3 nanogram per liter (ng/L)	Standard Deviation 28.4
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 1 Day 1	938 nanogram per liter (ng/L)	Standard Deviation 845
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 2 Day 5	1145 nanogram per liter (ng/L)	Standard Deviation 700
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 1 Day 1	254 nanogram per liter (ng/L)	Standard Deviation 177
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 1 Day 5	802 nanogram per liter (ng/L)	Standard Deviation 797
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	INF-γ: Cycle 1 Day 5	129 nanogram per liter (ng/L)	Standard Deviation 84.1
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	INF-γ: Cycle 2 Day 1	33.9 nanogram per liter (ng/L)	—
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 2 Day 1	351 nanogram per liter (ng/L)	Standard Deviation 448
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	INF-γ: Cycle 2 Day 5	45.1 nanogram per liter (ng/L)	Standard Deviation 28.5
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 2 Day 5	399 nanogram per liter (ng/L)	Standard Deviation 243
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	INF-γ: Cycle 1 Day 1	108 nanogram per liter (ng/L)	Standard Deviation 130
Part A, Dose Escalation: Nemvaleukin Alfa 8 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	INF-γ: Cycle 2 Day 5	171 nanogram per liter (ng/L)	Standard Deviation 78.4
Part A, Dose Escalation: Nemvaleukin Alfa 8 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	INF-γ: Cycle 1 Day 5	585 nanogram per liter (ng/L)	Standard Deviation 313
Part A, Dose Escalation: Nemvaleukin Alfa 8 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 2 Day 5	252 nanogram per liter (ng/L)	Standard Deviation 124
Part A, Dose Escalation: Nemvaleukin Alfa 8 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 1 Day 1	148 nanogram per liter (ng/L)	Standard Deviation 14.6
Part A, Dose Escalation: Nemvaleukin Alfa 8 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	INF-γ: Cycle 1 Day 1	26.4 nanogram per liter (ng/L)	—
Part A, Dose Escalation: Nemvaleukin Alfa 8 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	INF-γ: Cycle 2 Day 1	19.8 nanogram per liter (ng/L)	Standard Deviation 4.81
Part A, Dose Escalation: Nemvaleukin Alfa 8 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 2 Day 1	169 nanogram per liter (ng/L)	Standard Deviation 18.1
Part A, Dose Escalation: Nemvaleukin Alfa 8 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 1 Day 5	677 nanogram per liter (ng/L)	Standard Deviation 751
Part A, Dose Escalation: Nemvaleukin Alfa 10 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 2 Day 5	1372 nanogram per liter (ng/L)	Standard Deviation 1841
Part A, Dose Escalation: Nemvaleukin Alfa 10 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	INF-γ: Cycle 2 Day 1	15.7 nanogram per liter (ng/L)	—
Part A, Dose Escalation: Nemvaleukin Alfa 10 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	INF-γ: Cycle 1 Day 5	335 nanogram per liter (ng/L)	Standard Deviation 74.3
Part A, Dose Escalation: Nemvaleukin Alfa 10 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	INF-γ: Cycle 2 Day 5	84.8 nanogram per liter (ng/L)	Standard Deviation 58.6
Part A, Dose Escalation: Nemvaleukin Alfa 10 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 1 Day 5	5240 nanogram per liter (ng/L)	Standard Deviation 5279
Part A, Dose Escalation: Nemvaleukin Alfa 10 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	INF-γ: Cycle 1 Day 1	18.0 nanogram per liter (ng/L)	—
Part A, Dose Escalation: Nemvaleukin Alfa 10 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 1 Day 1	1826 nanogram per liter (ng/L)	Standard Deviation 3474
Part A, Dose Escalation: Nemvaleukin Alfa 10 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 2 Day 1	519 nanogram per liter (ng/L)	Standard Deviation 475
Part B, Dose Expansion, Melanoma: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	INF-γ: Cycle 2 Day 5	141 nanogram per liter (ng/L)	Standard Deviation 139
Part B, Dose Expansion, Melanoma: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 1 Day 1	323 nanogram per liter (ng/L)	Standard Deviation 630
Part B, Dose Expansion, Melanoma: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	INF-γ: Cycle 2 Day 1	43.3 nanogram per liter (ng/L)	Standard Deviation 41.9
Part B, Dose Expansion, Melanoma: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	INF-γ: Cycle 1 Day 1	34.7 nanogram per liter (ng/L)	Standard Deviation 22.7
Part B, Dose Expansion, Melanoma: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 1 Day 5	699 nanogram per liter (ng/L)	Standard Deviation 538
Part B, Dose Expansion, Melanoma: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 2 Day 1	311 nanogram per liter (ng/L)	Standard Deviation 447
Part B, Dose Expansion, Melanoma: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 2 Day 5	341 nanogram per liter (ng/L)	Standard Deviation 252
Part B, Dose Expansion, Melanoma: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	INF-γ: Cycle 1 Day 5	209 nanogram per liter (ng/L)	Standard Deviation 191
Part B, Dose Expansion, RCC: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	INF-γ: Cycle 1 Day 1	18.6 nanogram per liter (ng/L)	Standard Deviation 4.19
Part B, Dose Expansion, RCC: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	INF-γ: Cycle 2 Day 5	120 nanogram per liter (ng/L)	Standard Deviation 178
Part B, Dose Expansion, RCC: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 1 Day 5	723 nanogram per liter (ng/L)	Standard Deviation 1077
Part B, Dose Expansion, RCC: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 2 Day 5	318 nanogram per liter (ng/L)	Standard Deviation 174
Part B, Dose Expansion, RCC: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 2 Day 1	254 nanogram per liter (ng/L)	Standard Deviation 151
Part B, Dose Expansion, RCC: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	INF-γ: Cycle 2 Day 1	50.4 nanogram per liter (ng/L)	Standard Deviation 22.7
Part B, Dose Expansion, RCC: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 1 Day 1	211 nanogram per liter (ng/L)	Standard Deviation 143
Part B, Dose Expansion, RCC: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	INF-γ: Cycle 1 Day 5	162 nanogram per liter (ng/L)	Standard Deviation 183
Part C, Combination Therapy, Safety Run-in: Nemvaleukin Alfa 1 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 2 Day 1	95.7 nanogram per liter (ng/L)	—
Part C, Combination Therapy, Safety Run-in: Nemvaleukin Alfa 1 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 1 Day 5	151 nanogram per liter (ng/L)	—
Part C, Combination Therapy, Safety Run-in: Nemvaleukin Alfa 1 mcg/kg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 2 Day 5	116 nanogram per liter (ng/L)	Standard Deviation 33
Part C, Combination Therapy, Cohort 1 +Safety Run-in: Nemvaleukin Alfa 3 mcg/kg+Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 2 Day 5	425 nanogram per liter (ng/L)	Standard Deviation 339
Part C, Combination Therapy, Cohort 1 +Safety Run-in: Nemvaleukin Alfa 3 mcg/kg+Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	INF-γ: Cycle 2 Day 1	15.4 nanogram per liter (ng/L)	—
Part C, Combination Therapy, Cohort 1 +Safety Run-in: Nemvaleukin Alfa 3 mcg/kg+Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	INF-γ: Cycle 2 Day 5	60.3 nanogram per liter (ng/L)	Standard Deviation 19.5
Part C, Combination Therapy, Cohort 1 +Safety Run-in: Nemvaleukin Alfa 3 mcg/kg+Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	INF-γ: Cycle 1 Day 1	23.3 nanogram per liter (ng/L)	Standard Deviation 7.4
Part C, Combination Therapy, Cohort 1 +Safety Run-in: Nemvaleukin Alfa 3 mcg/kg+Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 2 Day 1	254 nanogram per liter (ng/L)	Standard Deviation 99.4
Part C, Combination Therapy, Cohort 1 +Safety Run-in: Nemvaleukin Alfa 3 mcg/kg+Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	INF-γ: Cycle 1 Day 5	48.2 nanogram per liter (ng/L)	Standard Deviation 30.3
Part C, Combination Therapy, Cohort 1 +Safety Run-in: Nemvaleukin Alfa 3 mcg/kg+Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 1 Day 1	506 nanogram per liter (ng/L)	Standard Deviation 137
Part C, Combination Therapy, Cohort 1 +Safety Run-in: Nemvaleukin Alfa 3 mcg/kg+Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 1 Day 5	524 nanogram per liter (ng/L)	Standard Deviation 180
Part C, Combination Therapy, Cohort 2: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	INF-γ: Cycle 2 Day 5	73.3 nanogram per liter (ng/L)	Standard Deviation 77.7
Part C, Combination Therapy, Cohort 2: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 2 Day 5	929 nanogram per liter (ng/L)	Standard Deviation 1962
Part C, Combination Therapy, Cohort 2: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	INF-γ: Cycle 1 Day 1	77.0 nanogram per liter (ng/L)	Standard Deviation 106
Part C, Combination Therapy, Cohort 2: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	INF-γ: Cycle 1 Day 5	92.6 nanogram per liter (ng/L)	Standard Deviation 86.4
Part C, Combination Therapy, Cohort 2: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	INF-γ: Cycle 2 Day 1	70.9 nanogram per liter (ng/L)	Standard Deviation 102
Part C, Combination Therapy, Cohort 2: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 1 Day 1	667 nanogram per liter (ng/L)	Standard Deviation 1020
Part C, Combination Therapy, Cohort 2: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 1 Day 5	1269 nanogram per liter (ng/L)	Standard Deviation 1807
Part C, Combination Therapy, Cohort 2: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 2 Day 1	669 nanogram per liter (ng/L)	Standard Deviation 1075
Part C, Combination Therapy, Cohort 3: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	INF-γ: Cycle 2 Day 1	21.1 nanogram per liter (ng/L)	Standard Deviation 6.39
Part C, Combination Therapy, Cohort 3: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	INF-γ: Cycle 2 Day 5	47.7 nanogram per liter (ng/L)	Standard Deviation 43.5
Part C, Combination Therapy, Cohort 3: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 2 Day 1	276 nanogram per liter (ng/L)	Standard Deviation 249
Part C, Combination Therapy, Cohort 3: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 2 Day 5	290 nanogram per liter (ng/L)	Standard Deviation 296
Part C, Combination Therapy, Cohort 3: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	INF-γ: Cycle 1 Day 1	34.5 nanogram per liter (ng/L)	Standard Deviation 15.6
Part C, Combination Therapy, Cohort 3: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 1 Day 5	513 nanogram per liter (ng/L)	Standard Deviation 585
Part C, Combination Therapy, Cohort 3: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 1 Day 1	274 nanogram per liter (ng/L)	Standard Deviation 234
Part C, Combination Therapy, Cohort 3: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	INF-γ: Cycle 1 Day 5	94.3 nanogram per liter (ng/L)	Standard Deviation 103
Part C, Combination Therapy, Rollover, Cohort 4: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 1 Day 1	306 nanogram per liter (ng/L)	Standard Deviation 181
Part C, Combination Therapy, Rollover, Cohort 4: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 1 Day 5	527 nanogram per liter (ng/L)	Standard Deviation 538
Part C, Combination Therapy, Rollover, Cohort 4: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 2 Day 5	269 nanogram per liter (ng/L)	Standard Deviation 155
Part C, Combination Therapy, Rollover, Cohort 4: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	INF-γ: Cycle 2 Day 5	38.5 nanogram per liter (ng/L)	Standard Deviation 22.2
Part C, Combination Therapy, Rollover, Cohort 4: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	INF-γ: Cycle 2 Day 1	19.7 nanogram per liter (ng/L)	Standard Deviation 3.87
Part C, Combination Therapy, Rollover, Cohort 4: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	INF-γ: Cycle 1 Day 5	70.9 nanogram per liter (ng/L)	Standard Deviation 54.7
Part C, Combination Therapy, Rollover, Cohort 4: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 2 Day 1	372 nanogram per liter (ng/L)	Standard Deviation 279
Part C, Combination Therapy, Rollover, Cohort 4: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	INF-γ: Cycle 1 Day 1	18.9 nanogram per liter (ng/L)	Standard Deviation 3.71
Part C, Combination Therapy, Cohort 5: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 1 Day 1	706 nanogram per liter (ng/L)	Standard Deviation 1757
Part C, Combination Therapy, Cohort 5: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 2 Day 1	282 nanogram per liter (ng/L)	Standard Deviation 176
Part C, Combination Therapy, Cohort 5: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 1 Day 5	273 nanogram per liter (ng/L)	Standard Deviation 244
Part C, Combination Therapy, Cohort 5: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	INF-γ: Cycle 1 Day 5	64.4 nanogram per liter (ng/L)	Standard Deviation 61.5
Part C, Combination Therapy, Cohort 5: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	INF-γ: Cycle 2 Day 5	54.0 nanogram per liter (ng/L)	Standard Deviation 36.1
Part C, Combination Therapy, Cohort 5: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 2 Day 5	269 nanogram per liter (ng/L)	Standard Deviation 174
Part C, Combination Therapy, Cohort 5: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	INF-γ: Cycle 2 Day 1	62.4 nanogram per liter (ng/L)	Standard Deviation 20.7
Part C, Combination Therapy, Cohort 5: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	INF-γ: Cycle 1 Day 1	84.4 nanogram per liter (ng/L)	Standard Deviation 87.8
Part C, Combination Therapy, Cohort 6: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 1 Day 1	200 nanogram per liter (ng/L)	Standard Deviation 101
Part C, Combination Therapy, Cohort 6: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 2 Day 5	165 nanogram per liter (ng/L)	Standard Deviation 98.6
Part C, Combination Therapy, Cohort 6: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	INF-γ: Cycle 1 Day 5	390 nanogram per liter (ng/L)	Standard Deviation 530
Part C, Combination Therapy, Cohort 6: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	INF-γ: Cycle 2 Day 5	326 nanogram per liter (ng/L)	Standard Deviation 124
Part C, Combination Therapy, Cohort 6: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 1 Day 5	1049 nanogram per liter (ng/L)	Standard Deviation 1288
Part C, Combination Therapy, Cohort 6: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 2 Day 1	718 nanogram per liter (ng/L)	Standard Deviation 649
Part C, Combination Therapy, Cohort 6: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	INF-γ: Cycle 1 Day 1	68.3 nanogram per liter (ng/L)	—
Part C, Combination Therapy, Cohort 6: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	INF-γ: Cycle 2 Day 1	43.5 nanogram per liter (ng/L)	—
Part C, Combination Therapy, Cohort 7: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 2 Day 1	264 nanogram per liter (ng/L)	Standard Deviation 379
Part C, Combination Therapy, Cohort 7: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	INF-γ: Cycle 1 Day 1	31.7 nanogram per liter (ng/L)	Standard Deviation 24.2
Part C, Combination Therapy, Cohort 7: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	INF-γ: Cycle 1 Day 5	279 nanogram per liter (ng/L)	Standard Deviation 526
Part C, Combination Therapy, Cohort 7: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	INF-γ: Cycle 2 Day 1	25.8 nanogram per liter (ng/L)	Standard Deviation 1.04
Part C, Combination Therapy, Cohort 7: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	INF-γ: Cycle 2 Day 5	101 nanogram per liter (ng/L)	Standard Deviation 71
Part C, Combination Therapy, Cohort 7: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 1 Day 1	757 nanogram per liter (ng/L)	Standard Deviation 2165
Part C, Combination Therapy, Cohort 7: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 1 Day 5	635 nanogram per liter (ng/L)	Standard Deviation 500
Part C, Combination Therapy, Cohort 7: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 2 Day 5	267 nanogram per liter (ng/L)	Standard Deviation 172
Part C, Combination Therapy, Cohort 7: Nemvaleukin 6 Alfa mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	INF-γ: Cycle 2 Day 5	41.9 nanogram per liter (ng/L)	Standard Deviation 1.42
Part C, Combination Therapy, Cohort 7: Nemvaleukin 6 Alfa mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	INF-γ: Cycle 1 Day 5	87.7 nanogram per liter (ng/L)	Standard Deviation 42.1
Part C, Combination Therapy, Cohort 7: Nemvaleukin 6 Alfa mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 2 Day 5	123 nanogram per liter (ng/L)	Standard Deviation 19
Part C, Combination Therapy, Cohort 7: Nemvaleukin 6 Alfa mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)	IL-6: Cycle 1 Day 5	232 nanogram per liter (ng/L)	Standard Deviation 13.8

Secondary

Parts A, B and C: Maximum Cell Count of Whole Blood FoxP3+ T Cells (Tregs), Total Cluster of Differentiation (CD)8+ T Cells and Natural Killer (NK) Cells

Time frame: Cycle 1 Day 1 (Cycle 1 length = 14 days for Part A and 21 days for Part B and C)

Population: The pharmacodynamic (PD) population consisted of all participants who received at least 1 dose of nemvaleukin alfa and had at least one available postbaseline PD measurement. Here, overall number of participants analyzed signifies participants who were evaluable for this outcome measure and number analyzed signifies participants who were evaluable at specified timepoints.

Arm	Measure	Group	Value (MEAN)	Dispersion
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Parts A, B and C: Maximum Cell Count of Whole Blood FoxP3+ T Cells (Tregs), Total Cluster of Differentiation (CD)8+ T Cells and Natural Killer (NK) Cells	NK Cells	197 cells per microliters (cells/mcL)	Standard Deviation 61.4
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Parts A, B and C: Maximum Cell Count of Whole Blood FoxP3+ T Cells (Tregs), Total Cluster of Differentiation (CD)8+ T Cells and Natural Killer (NK) Cells	Whole Blood FoxP3+ T Cells (Tregs)	32.0 cells per microliters (cells/mcL)	Standard Deviation 11.3
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Parts A, B and C: Maximum Cell Count of Whole Blood FoxP3+ T Cells (Tregs), Total Cluster of Differentiation (CD)8+ T Cells and Natural Killer (NK) Cells	Total CD8+ T Cells	247 cells per microliters (cells/mcL)	Standard Deviation 107
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Parts A, B and C: Maximum Cell Count of Whole Blood FoxP3+ T Cells (Tregs), Total Cluster of Differentiation (CD)8+ T Cells and Natural Killer (NK) Cells	Whole Blood FoxP3+ T Cells (Tregs)	50.5 cells per microliters (cells/mcL)	Standard Deviation 53.7
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Parts A, B and C: Maximum Cell Count of Whole Blood FoxP3+ T Cells (Tregs), Total Cluster of Differentiation (CD)8+ T Cells and Natural Killer (NK) Cells	Total CD8+ T Cells	204 cells per microliters (cells/mcL)	Standard Deviation 89.2
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Parts A, B and C: Maximum Cell Count of Whole Blood FoxP3+ T Cells (Tregs), Total Cluster of Differentiation (CD)8+ T Cells and Natural Killer (NK) Cells	NK Cells	343 cells per microliters (cells/mcL)	Standard Deviation 20.6
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Parts A, B and C: Maximum Cell Count of Whole Blood FoxP3+ T Cells (Tregs), Total Cluster of Differentiation (CD)8+ T Cells and Natural Killer (NK) Cells	Total CD8+ T Cells	262 cells per microliters (cells/mcL)	Standard Deviation 64.2
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Parts A, B and C: Maximum Cell Count of Whole Blood FoxP3+ T Cells (Tregs), Total Cluster of Differentiation (CD)8+ T Cells and Natural Killer (NK) Cells	Whole Blood FoxP3+ T Cells (Tregs)	56.6 cells per microliters (cells/mcL)	Standard Deviation 22.3
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Parts A, B and C: Maximum Cell Count of Whole Blood FoxP3+ T Cells (Tregs), Total Cluster of Differentiation (CD)8+ T Cells and Natural Killer (NK) Cells	NK Cells	467 cells per microliters (cells/mcL)	Standard Deviation 313
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Parts A, B and C: Maximum Cell Count of Whole Blood FoxP3+ T Cells (Tregs), Total Cluster of Differentiation (CD)8+ T Cells and Natural Killer (NK) Cells	NK Cells	685 cells per microliters (cells/mcL)	Standard Deviation 307
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Parts A, B and C: Maximum Cell Count of Whole Blood FoxP3+ T Cells (Tregs), Total Cluster of Differentiation (CD)8+ T Cells and Natural Killer (NK) Cells	Whole Blood FoxP3+ T Cells (Tregs)	46.3 cells per microliters (cells/mcL)	Standard Deviation 21.8
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Parts A, B and C: Maximum Cell Count of Whole Blood FoxP3+ T Cells (Tregs), Total Cluster of Differentiation (CD)8+ T Cells and Natural Killer (NK) Cells	Total CD8+ T Cells	466 cells per microliters (cells/mcL)	Standard Deviation 255
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Maximum Cell Count of Whole Blood FoxP3+ T Cells (Tregs), Total Cluster of Differentiation (CD)8+ T Cells and Natural Killer (NK) Cells	Total CD8+ T Cells	610 cells per microliters (cells/mcL)	Standard Deviation 570
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Maximum Cell Count of Whole Blood FoxP3+ T Cells (Tregs), Total Cluster of Differentiation (CD)8+ T Cells and Natural Killer (NK) Cells	Whole Blood FoxP3+ T Cells (Tregs)	43.3 cells per microliters (cells/mcL)	Standard Deviation 28.2
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Maximum Cell Count of Whole Blood FoxP3+ T Cells (Tregs), Total Cluster of Differentiation (CD)8+ T Cells and Natural Killer (NK) Cells	NK Cells	1053 cells per microliters (cells/mcL)	Standard Deviation 660
Part A, Dose Escalation: Nemvaleukin Alfa 8 mcg/kg	Parts A, B and C: Maximum Cell Count of Whole Blood FoxP3+ T Cells (Tregs), Total Cluster of Differentiation (CD)8+ T Cells and Natural Killer (NK) Cells	NK Cells	978 cells per microliters (cells/mcL)	Standard Deviation 400
Part A, Dose Escalation: Nemvaleukin Alfa 8 mcg/kg	Parts A, B and C: Maximum Cell Count of Whole Blood FoxP3+ T Cells (Tregs), Total Cluster of Differentiation (CD)8+ T Cells and Natural Killer (NK) Cells	Whole Blood FoxP3+ T Cells (Tregs)	57.4 cells per microliters (cells/mcL)	Standard Deviation 14.4
Part A, Dose Escalation: Nemvaleukin Alfa 8 mcg/kg	Parts A, B and C: Maximum Cell Count of Whole Blood FoxP3+ T Cells (Tregs), Total Cluster of Differentiation (CD)8+ T Cells and Natural Killer (NK) Cells	Total CD8+ T Cells	704 cells per microliters (cells/mcL)	Standard Deviation 559
Part A, Dose Escalation: Nemvaleukin Alfa 10 mcg/kg	Parts A, B and C: Maximum Cell Count of Whole Blood FoxP3+ T Cells (Tregs), Total Cluster of Differentiation (CD)8+ T Cells and Natural Killer (NK) Cells	NK Cells	1038 cells per microliters (cells/mcL)	Standard Deviation 1028
Part A, Dose Escalation: Nemvaleukin Alfa 10 mcg/kg	Parts A, B and C: Maximum Cell Count of Whole Blood FoxP3+ T Cells (Tregs), Total Cluster of Differentiation (CD)8+ T Cells and Natural Killer (NK) Cells	Whole Blood FoxP3+ T Cells (Tregs)	51.3 cells per microliters (cells/mcL)	Standard Deviation 36
Part A, Dose Escalation: Nemvaleukin Alfa 10 mcg/kg	Parts A, B and C: Maximum Cell Count of Whole Blood FoxP3+ T Cells (Tregs), Total Cluster of Differentiation (CD)8+ T Cells and Natural Killer (NK) Cells	Total CD8+ T Cells	703 cells per microliters (cells/mcL)	Standard Deviation 502
Part B, Dose Expansion, Melanoma: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Maximum Cell Count of Whole Blood FoxP3+ T Cells (Tregs), Total Cluster of Differentiation (CD)8+ T Cells and Natural Killer (NK) Cells	Whole Blood FoxP3+ T Cells (Tregs)	40.3 cells per microliters (cells/mcL)	Standard Deviation 23.5
Part B, Dose Expansion, Melanoma: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Maximum Cell Count of Whole Blood FoxP3+ T Cells (Tregs), Total Cluster of Differentiation (CD)8+ T Cells and Natural Killer (NK) Cells	Total CD8+ T Cells	1392 cells per microliters (cells/mcL)	Standard Deviation 1053
Part B, Dose Expansion, Melanoma: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Maximum Cell Count of Whole Blood FoxP3+ T Cells (Tregs), Total Cluster of Differentiation (CD)8+ T Cells and Natural Killer (NK) Cells	NK Cells	1279 cells per microliters (cells/mcL)	Standard Deviation 642
Part B, Dose Expansion, RCC: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Maximum Cell Count of Whole Blood FoxP3+ T Cells (Tregs), Total Cluster of Differentiation (CD)8+ T Cells and Natural Killer (NK) Cells	Total CD8+ T Cells	773 cells per microliters (cells/mcL)	Standard Deviation 422
Part B, Dose Expansion, RCC: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Maximum Cell Count of Whole Blood FoxP3+ T Cells (Tregs), Total Cluster of Differentiation (CD)8+ T Cells and Natural Killer (NK) Cells	NK Cells	1470 cells per microliters (cells/mcL)	Standard Deviation 873
Part B, Dose Expansion, RCC: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Maximum Cell Count of Whole Blood FoxP3+ T Cells (Tregs), Total Cluster of Differentiation (CD)8+ T Cells and Natural Killer (NK) Cells	Whole Blood FoxP3+ T Cells (Tregs)	47.9 cells per microliters (cells/mcL)	Standard Deviation 24
Part C, Combination Therapy, Safety Run-in: Nemvaleukin Alfa 1 mcg/kg	Parts A, B and C: Maximum Cell Count of Whole Blood FoxP3+ T Cells (Tregs), Total Cluster of Differentiation (CD)8+ T Cells and Natural Killer (NK) Cells	Total CD8+ T Cells	262 cells per microliters (cells/mcL)	Standard Deviation 186
Part C, Combination Therapy, Safety Run-in: Nemvaleukin Alfa 1 mcg/kg	Parts A, B and C: Maximum Cell Count of Whole Blood FoxP3+ T Cells (Tregs), Total Cluster of Differentiation (CD)8+ T Cells and Natural Killer (NK) Cells	Whole Blood FoxP3+ T Cells (Tregs)	27.4 cells per microliters (cells/mcL)	Standard Deviation 7.31
Part C, Combination Therapy, Safety Run-in: Nemvaleukin Alfa 1 mcg/kg	Parts A, B and C: Maximum Cell Count of Whole Blood FoxP3+ T Cells (Tregs), Total Cluster of Differentiation (CD)8+ T Cells and Natural Killer (NK) Cells	NK Cells	531 cells per microliters (cells/mcL)	Standard Deviation 296
Part C, Combination Therapy, Cohort 1 +Safety Run-in: Nemvaleukin Alfa 3 mcg/kg+Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Whole Blood FoxP3+ T Cells (Tregs), Total Cluster of Differentiation (CD)8+ T Cells and Natural Killer (NK) Cells	Total CD8+ T Cells	551 cells per microliters (cells/mcL)	Standard Deviation 433
Part C, Combination Therapy, Cohort 1 +Safety Run-in: Nemvaleukin Alfa 3 mcg/kg+Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Whole Blood FoxP3+ T Cells (Tregs), Total Cluster of Differentiation (CD)8+ T Cells and Natural Killer (NK) Cells	NK Cells	804 cells per microliters (cells/mcL)	Standard Deviation 196
Part C, Combination Therapy, Cohort 1 +Safety Run-in: Nemvaleukin Alfa 3 mcg/kg+Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Whole Blood FoxP3+ T Cells (Tregs), Total Cluster of Differentiation (CD)8+ T Cells and Natural Killer (NK) Cells	Whole Blood FoxP3+ T Cells (Tregs)	50.9 cells per microliters (cells/mcL)	Standard Deviation 23.9
Part C, Combination Therapy, Cohort 2: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Whole Blood FoxP3+ T Cells (Tregs), Total Cluster of Differentiation (CD)8+ T Cells and Natural Killer (NK) Cells	Total CD8+ T Cells	562 cells per microliters (cells/mcL)	Standard Deviation 373
Part C, Combination Therapy, Cohort 2: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Whole Blood FoxP3+ T Cells (Tregs), Total Cluster of Differentiation (CD)8+ T Cells and Natural Killer (NK) Cells	NK Cells	771 cells per microliters (cells/mcL)	Standard Deviation 503
Part C, Combination Therapy, Cohort 2: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Whole Blood FoxP3+ T Cells (Tregs), Total Cluster of Differentiation (CD)8+ T Cells and Natural Killer (NK) Cells	Whole Blood FoxP3+ T Cells (Tregs)	42.6 cells per microliters (cells/mcL)	Standard Deviation 28.3
Part C, Combination Therapy, Cohort 3: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Whole Blood FoxP3+ T Cells (Tregs), Total Cluster of Differentiation (CD)8+ T Cells and Natural Killer (NK) Cells	Whole Blood FoxP3+ T Cells (Tregs)	37.8 cells per microliters (cells/mcL)	Standard Deviation 24.5
Part C, Combination Therapy, Cohort 3: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Whole Blood FoxP3+ T Cells (Tregs), Total Cluster of Differentiation (CD)8+ T Cells and Natural Killer (NK) Cells	Total CD8+ T Cells	533 cells per microliters (cells/mcL)	Standard Deviation 328
Part C, Combination Therapy, Cohort 3: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Whole Blood FoxP3+ T Cells (Tregs), Total Cluster of Differentiation (CD)8+ T Cells and Natural Killer (NK) Cells	NK Cells	760 cells per microliters (cells/mcL)	Standard Deviation 458
Part C, Combination Therapy, Rollover, Cohort 4: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Whole Blood FoxP3+ T Cells (Tregs), Total Cluster of Differentiation (CD)8+ T Cells and Natural Killer (NK) Cells	Whole Blood FoxP3+ T Cells (Tregs)	41.6 cells per microliters (cells/mcL)	Standard Deviation 27.7
Part C, Combination Therapy, Rollover, Cohort 4: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Whole Blood FoxP3+ T Cells (Tregs), Total Cluster of Differentiation (CD)8+ T Cells and Natural Killer (NK) Cells	NK Cells	813 cells per microliters (cells/mcL)	Standard Deviation 436
Part C, Combination Therapy, Rollover, Cohort 4: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Whole Blood FoxP3+ T Cells (Tregs), Total Cluster of Differentiation (CD)8+ T Cells and Natural Killer (NK) Cells	Total CD8+ T Cells	688 cells per microliters (cells/mcL)	Standard Deviation 384
Part C, Combination Therapy, Cohort 5: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Whole Blood FoxP3+ T Cells (Tregs), Total Cluster of Differentiation (CD)8+ T Cells and Natural Killer (NK) Cells	Total CD8+ T Cells	718 cells per microliters (cells/mcL)	Standard Deviation 567
Part C, Combination Therapy, Cohort 5: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Whole Blood FoxP3+ T Cells (Tregs), Total Cluster of Differentiation (CD)8+ T Cells and Natural Killer (NK) Cells	Whole Blood FoxP3+ T Cells (Tregs)	44.3 cells per microliters (cells/mcL)	Standard Deviation 22.5
Part C, Combination Therapy, Cohort 5: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Whole Blood FoxP3+ T Cells (Tregs), Total Cluster of Differentiation (CD)8+ T Cells and Natural Killer (NK) Cells	NK Cells	889 cells per microliters (cells/mcL)	Standard Deviation 438
Part C, Combination Therapy, Cohort 6: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Whole Blood FoxP3+ T Cells (Tregs), Total Cluster of Differentiation (CD)8+ T Cells and Natural Killer (NK) Cells	Whole Blood FoxP3+ T Cells (Tregs)	51.1 cells per microliters (cells/mcL)	Standard Deviation 9.85
Part C, Combination Therapy, Cohort 6: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Whole Blood FoxP3+ T Cells (Tregs), Total Cluster of Differentiation (CD)8+ T Cells and Natural Killer (NK) Cells	Total CD8+ T Cells	924 cells per microliters (cells/mcL)	Standard Deviation 638
Part C, Combination Therapy, Cohort 6: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Whole Blood FoxP3+ T Cells (Tregs), Total Cluster of Differentiation (CD)8+ T Cells and Natural Killer (NK) Cells	NK Cells	1081 cells per microliters (cells/mcL)	Standard Deviation 787
Part C, Combination Therapy, Cohort 7: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Whole Blood FoxP3+ T Cells (Tregs), Total Cluster of Differentiation (CD)8+ T Cells and Natural Killer (NK) Cells	Total CD8+ T Cells	762 cells per microliters (cells/mcL)	Standard Deviation 538
Part C, Combination Therapy, Cohort 7: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Whole Blood FoxP3+ T Cells (Tregs), Total Cluster of Differentiation (CD)8+ T Cells and Natural Killer (NK) Cells	NK Cells	1064 cells per microliters (cells/mcL)	Standard Deviation 445
Part C, Combination Therapy, Cohort 7: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Whole Blood FoxP3+ T Cells (Tregs), Total Cluster of Differentiation (CD)8+ T Cells and Natural Killer (NK) Cells	Whole Blood FoxP3+ T Cells (Tregs)	52.6 cells per microliters (cells/mcL)	Standard Deviation 31.3
Part C, Combination Therapy, Cohort 7: Nemvaleukin 6 Alfa mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Whole Blood FoxP3+ T Cells (Tregs), Total Cluster of Differentiation (CD)8+ T Cells and Natural Killer (NK) Cells	Total CD8+ T Cells	445 cells per microliters (cells/mcL)	Standard Deviation 349
Part C, Combination Therapy, Cohort 7: Nemvaleukin 6 Alfa mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Whole Blood FoxP3+ T Cells (Tregs), Total Cluster of Differentiation (CD)8+ T Cells and Natural Killer (NK) Cells	Whole Blood FoxP3+ T Cells (Tregs)	33.1 cells per microliters (cells/mcL)	—
Part C, Combination Therapy, Cohort 7: Nemvaleukin 6 Alfa mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Cell Count of Whole Blood FoxP3+ T Cells (Tregs), Total Cluster of Differentiation (CD)8+ T Cells and Natural Killer (NK) Cells	NK Cells	1298 cells per microliters (cells/mcL)	Standard Deviation 334

Secondary

Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa

Cycle 1 length = 14 days for Part A and 21 days for Part B and C; Cycle 2 length= 21 days for all parts.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)	Dispersion
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 2 Day 1	1.72 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 35.1
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 1 Day 5	1.99 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 10.3
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 2 Day 5	1.90 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 11
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 1 Day 1	2.09 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 41.4
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 2 Day 1	5.34 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 2.2
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 1 Day 1	6.72 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 21.3
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 1 Day 5	6.36 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 24.5
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 2 Day 5	6.39 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 12.7
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 1 Day 5	37.4 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 19.2
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 2 Day 1	19.8 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 32.3
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 1 Day 1	20.5 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 26.8
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 2 Day 5	16.7 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 18.5
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 1 Day 1	47.6 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 177.8
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 2 Day 5	52.9 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 48.1
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 1 Day 5	41.8 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 178.7
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 2 Day 1	65.3 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 27.5
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 2 Day 5	97.4 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 29
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 2 Day 1	113 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 24.7
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 1 Day 1	113 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 33.7
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 1 Day 5	108 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 22.5
Part A, Dose Escalation: Nemvaleukin Alfa 8 mcg/kg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 1 Day 5	112 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 13.5
Part A, Dose Escalation: Nemvaleukin Alfa 8 mcg/kg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 1 Day 1	151 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 36.7
Part A, Dose Escalation: Nemvaleukin Alfa 8 mcg/kg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 2 Day 1	112 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 13
Part A, Dose Escalation: Nemvaleukin Alfa 8 mcg/kg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 2 Day 5	95.7 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 37
Part A, Dose Escalation: Nemvaleukin Alfa 10 mcg/kg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 2 Day 5	83.8 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 57.4
Part A, Dose Escalation: Nemvaleukin Alfa 10 mcg/kg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 1 Day 5	104 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 12.5
Part A, Dose Escalation: Nemvaleukin Alfa 10 mcg/kg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 2 Day 1	116 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 33.1
Part A, Dose Escalation: Nemvaleukin Alfa 10 mcg/kg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 1 Day 1	157 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 19.4
Part B, Dose Expansion, Melanoma: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 1 Day 1	99.4 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 40.8
Part B, Dose Expansion, Melanoma: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 2 Day 1	108 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 86.7
Part B, Dose Expansion, Melanoma: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 2 Day 5	103 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 69.5
Part B, Dose Expansion, Melanoma: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 1 Day 5	82.1 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 32.3
Part B, Dose Expansion, RCC: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 1 Day 5	95.1 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 33.8
Part B, Dose Expansion, RCC: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 1 Day 1	124 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 34.2
Part B, Dose Expansion, RCC: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 2 Day 1	119 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 27.6
Part B, Dose Expansion, RCC: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 2 Day 5	99.6 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 18.3
Part C, Combination Therapy, Safety Run-in: Nemvaleukin Alfa 1 mcg/kg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 2 Day 1	15.6 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 18.1
Part C, Combination Therapy, Safety Run-in: Nemvaleukin Alfa 1 mcg/kg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 1 Day 1	18.1 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 15.4
Part C, Combination Therapy, Safety Run-in: Nemvaleukin Alfa 1 mcg/kg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 1 Day 5	19.2 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 21.7
Part C, Combination Therapy, Safety Run-in: Nemvaleukin Alfa 1 mcg/kg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 2 Day 5	14.6 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 24
Part C, Combination Therapy, Cohort 1 +Safety Run-in: Nemvaleukin Alfa 3 mcg/kg+Pembrolizumab 200 mg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 1 Day 1	65.6 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 24.4
Part C, Combination Therapy, Cohort 1 +Safety Run-in: Nemvaleukin Alfa 3 mcg/kg+Pembrolizumab 200 mg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 1 Day 5	46.5 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 41.6
Part C, Combination Therapy, Cohort 1 +Safety Run-in: Nemvaleukin Alfa 3 mcg/kg+Pembrolizumab 200 mg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 2 Day 1	52.9 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 21.9
Part C, Combination Therapy, Cohort 1 +Safety Run-in: Nemvaleukin Alfa 3 mcg/kg+Pembrolizumab 200 mg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 2 Day 5	40.8 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 26.9
Part C, Combination Therapy, Cohort 2: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 1 Day 5	55.8 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 37.5
Part C, Combination Therapy, Cohort 2: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 1 Day 1	61.4 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 22.8
Part C, Combination Therapy, Cohort 2: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 2 Day 1	55.8 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 26.9
Part C, Combination Therapy, Cohort 2: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 2 Day 5	50.3 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 67.9
Part C, Combination Therapy, Cohort 3: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 2 Day 1	58.1 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 81.2
Part C, Combination Therapy, Cohort 3: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 1 Day 5	53.1 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 57.9
Part C, Combination Therapy, Cohort 3: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 1 Day 1	57.5 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 86.5
Part C, Combination Therapy, Cohort 3: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 2 Day 5	51.7 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 52
Part C, Combination Therapy, Rollover, Cohort 4: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 2 Day 5	51.0 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 25.9
Part C, Combination Therapy, Rollover, Cohort 4: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 1 Day 5	54.4 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 51.8
Part C, Combination Therapy, Rollover, Cohort 4: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 2 Day 1	55.6 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 31.4
Part C, Combination Therapy, Rollover, Cohort 4: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 1 Day 1	59.5 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 32.6
Part C, Combination Therapy, Cohort 5: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 1 Day 5	47.0 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 40.1
Part C, Combination Therapy, Cohort 5: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 1 Day 1	45.8 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 48.8
Part C, Combination Therapy, Cohort 5: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 2 Day 1	47.2 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 47.7
Part C, Combination Therapy, Cohort 5: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 2 Day 5	49.8 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 52.6
Part C, Combination Therapy, Cohort 6: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 2 Day 5	99.2 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 20.3
Part C, Combination Therapy, Cohort 6: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 1 Day 1	131 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 15.8
Part C, Combination Therapy, Cohort 6: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 1 Day 5	118 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 1.8
Part C, Combination Therapy, Cohort 6: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 2 Day 1	112 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 15.3
Part C, Combination Therapy, Cohort 7: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 1 Day 5	101 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 51.5
Part C, Combination Therapy, Cohort 7: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 2 Day 1	128 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 30.6
Part C, Combination Therapy, Cohort 7: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 1 Day 1	133 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 31.7
Part C, Combination Therapy, Cohort 7: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 2 Day 5	96.6 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 29.7
Part C, Combination Therapy, Cohort 7: Nemvaleukin 6 Alfa mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 1 Day 1	89.3 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 3
Part C, Combination Therapy, Cohort 7: Nemvaleukin 6 Alfa mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 2 Day 1	124 nanograms per milliliters (ng/mL)	—
Part C, Combination Therapy, Cohort 7: Nemvaleukin 6 Alfa mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 1 Day 5	104 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 1.8
Part C, Combination Therapy, Cohort 7: Nemvaleukin 6 Alfa mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa	Cycle 2 Day 5	94.4 nanograms per milliliters (ng/mL)	Geometric Coefficient of Variation 12.5

Secondary

Parts A, B, and C: Proportion of Positive Anti-Nemvaleukin Alfa Antibodies (ADA)

Overall proportion was calculated as: Number of participants (overall positive)/total number of participants in the cohort. Overall positive: Participants with at least 1 treatment-emergent ADA positive sample at any time during the treatment period.

Time frame: From first dose of study drug up to 9 months (for Part A); up to 40.3 months (for Part B); up to 50.5 months (for Part C)

Population: Immunogenicity analysis set included all participants who received at least one dose of active study drug and had at least one post baseline blood sample collected to assess immunogenicity.

Arm	Measure	Value (NUMBER)
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Parts A, B, and C: Proportion of Positive Anti-Nemvaleukin Alfa Antibodies (ADA)	0.00 proportion of participants
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Parts A, B, and C: Proportion of Positive Anti-Nemvaleukin Alfa Antibodies (ADA)	0.00 proportion of participants
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Proportion of Positive Anti-Nemvaleukin Alfa Antibodies (ADA)	0.143 proportion of participants
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Parts A, B, and C: Proportion of Positive Anti-Nemvaleukin Alfa Antibodies (ADA)	0.125 proportion of participants
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Proportion of Positive Anti-Nemvaleukin Alfa Antibodies (ADA)	0.417 proportion of participants
Part A, Dose Escalation: Nemvaleukin Alfa 8 mcg/kg	Parts A, B, and C: Proportion of Positive Anti-Nemvaleukin Alfa Antibodies (ADA)	0.333 proportion of participants
Part A, Dose Escalation: Nemvaleukin Alfa 10 mcg/kg	Parts A, B, and C: Proportion of Positive Anti-Nemvaleukin Alfa Antibodies (ADA)	0.600 proportion of participants
Part B, Dose Expansion, Melanoma: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Proportion of Positive Anti-Nemvaleukin Alfa Antibodies (ADA)	0.467 proportion of participants
Part B, Dose Expansion, RCC: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Proportion of Positive Anti-Nemvaleukin Alfa Antibodies (ADA)	0.500 proportion of participants
Part C, Combination Therapy, Safety Run-in: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Proportion of Positive Anti-Nemvaleukin Alfa Antibodies (ADA)	0.00 proportion of participants
Part C, Combination Therapy, Cohort 1 +Safety Run-in: Nemvaleukin Alfa 3 mcg/kg+Pembrolizumab 200 mg	Parts A, B, and C: Proportion of Positive Anti-Nemvaleukin Alfa Antibodies (ADA)	0.667 proportion of participants
Part C, Combination Therapy, Cohort 2: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Proportion of Positive Anti-Nemvaleukin Alfa Antibodies (ADA)	0.294 proportion of participants
Part C, Combination Therapy, Cohort 3: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Proportion of Positive Anti-Nemvaleukin Alfa Antibodies (ADA)	0.250 proportion of participants
Part C, Combination Therapy, Rollover, Cohort 4: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Proportion of Positive Anti-Nemvaleukin Alfa Antibodies (ADA)	0.208 proportion of participants
Part C, Combination Therapy, Cohort 5: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Proportion of Positive Anti-Nemvaleukin Alfa Antibodies (ADA)	0.581 proportion of participants
Part C, Combination Therapy, Cohort 6: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Proportion of Positive Anti-Nemvaleukin Alfa Antibodies (ADA)	0.667 proportion of participants
Part C, Combination Therapy, Cohort 7: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Proportion of Positive Anti-Nemvaleukin Alfa Antibodies (ADA)	0.200 proportion of participants
Part C, Combination Therapy, Cohort 7: Nemvaleukin 6 Alfa mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Proportion of Positive Anti-Nemvaleukin Alfa Antibodies (ADA)	0.00 proportion of participants

Secondary

Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa

Cycle 1 length = 14 days for Part A and 21 days for Part B and C; Cycle 2 length= 21 days for all parts.

Population: The pharmacokinetic (PK) population consisted of all participants who received at least 1 dose of nemvaleukin alfa and had at least 1 measurable serum concentration of nemvaleukin alfa at any scheduled PK time point. Here, overall number of participants analyzed signifies participants who were evaluable for this outcome measure and number analyzed signifies participants who were evaluable at specified timepoints.

Arm	Measure	Group	Value (MEAN)	Dispersion
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 2 hours	0.909 nanograms per milliliter (ng/mL)	Standard Deviation 0.164
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 16 hours	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 1 hour	1.44 nanograms per milliliter (ng/mL)	Standard Deviation 0.26
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 4 hours	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 16 hours	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 0 hour	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 8 hours	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 16 hours	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 24 hours	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 72 hours	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 0.5 hour	1.92 nanograms per milliliter (ng/mL)	Standard Deviation 0.296
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 24 hours	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 24 hours	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 240 hours	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 1 hour	1.61 nanograms per milliliter (ng/mL)	Standard Deviation 0.265
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 2 hours	0.965 nanograms per milliliter (ng/mL)	Standard Deviation 0.0894
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 8 hours	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 4 hours	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 4 hours	0.142 nanograms per milliliter (ng/mL)	Standard Deviation 0.318
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 4 hours	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 0 hour	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 2 hours	0.889 nanograms per milliliter (ng/mL)	Standard Deviation 0.174
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 8 hours	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 16 hours	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 0.5 hour	2.24 nanograms per milliliter (ng/mL)	Standard Deviation 1.06
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 1 hour	1.36 nanograms per milliliter (ng/mL)	Standard Deviation 0.646
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 24 hours	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 0 hour	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 8 hours	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 0.5 hour	1.80 nanograms per milliliter (ng/mL)	Standard Deviation 0.59
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 2 hours	0.988 nanograms per milliliter (ng/mL)	Standard Deviation 0.0219
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 0 hour	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 72 hours	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 0.5 hour	2.00 nanograms per milliliter (ng/mL)	Standard Deviation 0.238
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 1 hour	1.55 nanograms per milliliter (ng/mL)	Standard Deviation 0.245
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 8 hours	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 8 hours	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 24 hours	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 72 hours	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 4 hours	1.31 nanograms per milliliter (ng/mL)	Standard Deviation 0.422
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 24 hours	0.205 nanograms per milliliter (ng/mL)	Standard Deviation 0.41
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 2 hours	3.43 nanograms per milliliter (ng/mL)	Standard Deviation 0.797
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 1 hour	4.84 nanograms per milliliter (ng/mL)	Standard Deviation 0.806
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 0.5 hour	5.42 nanograms per milliliter (ng/mL)	—
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 0 hour	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 0 hour	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 72 hours	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 24 hours	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 0.5 hour	6.06 nanograms per milliliter (ng/mL)	Standard Deviation 0.454
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 16 hours	0.158 nanograms per milliliter (ng/mL)	Standard Deviation 0.316
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 8 hours	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 4 hours	1.17 nanograms per milliliter (ng/mL)	Standard Deviation 0.45
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 1 hour	4.82 nanograms per milliliter (ng/mL)	Standard Deviation 0.794
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 2 hours	3.53 nanograms per milliliter (ng/mL)	Standard Deviation 1.1
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 1 hour	5.28 nanograms per milliliter (ng/mL)	Standard Deviation 1.07
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 0.5 hour	6.00 nanograms per milliliter (ng/mL)	Standard Deviation 1.45
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 2 hours	2.84 nanograms per milliliter (ng/mL)	Standard Deviation 0.751
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 0 hour	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 16 hours	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 24 hours	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 16 hours	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 8 hours	0.453 nanograms per milliliter (ng/mL)	Standard Deviation 0.314
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 4 hours	1.13 nanograms per milliliter (ng/mL)	Standard Deviation 0.471
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 4 hours	1.87 nanograms per milliliter (ng/mL)	Standard Deviation 0.71
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 2 hours	3.83 nanograms per milliliter (ng/mL)	Standard Deviation 1.01
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 1 hour	5.67 nanograms per milliliter (ng/mL)	Standard Deviation 1.61
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 16 hours	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 0.5 hour	6.13 nanograms per milliliter (ng/mL)	Standard Deviation 0.653
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 0 hour	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 240 hours	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 8 hours	2.32 nanograms per milliliter (ng/mL)	Standard Deviation 1.45
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 2 hours	9.26 nanograms per milliliter (ng/mL)	Standard Deviation 5.76
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 8 hours	1.27 nanograms per milliliter (ng/mL)	Standard Deviation 0.509
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 1 hour	13.8 nanograms per milliliter (ng/mL)	Standard Deviation 7.79
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 0.5 hour	20.1 nanograms per milliliter (ng/mL)	Standard Deviation 8.08
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 0 hour	0.0868 nanograms per milliliter (ng/mL)	Standard Deviation 0.213
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 0 hour	0.104 nanograms per milliliter (ng/mL)	Standard Deviation 0.276
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 0.5 hour	20.1 nanograms per milliliter (ng/mL)	Standard Deviation 5.32
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 2 hours	9.09 nanograms per milliliter (ng/mL)	Standard Deviation 3.13
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 0.5 hour	20.7 nanograms per milliliter (ng/mL)	Standard Deviation 6.83
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 24 hours	0.106 nanograms per milliliter (ng/mL)	Standard Deviation 0.28
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 16 hours	0.522 nanograms per milliliter (ng/mL)	Standard Deviation 0.641
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 0 hour	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 1 hour	17.3 nanograms per milliliter (ng/mL)	Standard Deviation 5.46
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 8 hours	2.55 nanograms per milliliter (ng/mL)	Standard Deviation 1.27
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 72 hours	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 2 hours	12.6 nanograms per milliliter (ng/mL)	Standard Deviation 4.4
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 24 hours	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 4 hours	4.18 nanograms per milliliter (ng/mL)	Standard Deviation 1.98
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 16 hours	0.405 nanograms per milliliter (ng/mL)	Standard Deviation 0.701
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 4 hours	6.97 nanograms per milliliter (ng/mL)	Standard Deviation 2.25
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 2 hours	12.3 nanograms per milliliter (ng/mL)	Standard Deviation 2.8
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 240 hours	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 1 hour	16.6 nanograms per milliliter (ng/mL)	Standard Deviation 3.84
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 24 hours	0.147 nanograms per milliliter (ng/mL)	Standard Deviation 0.294
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 16 hours	0.218 nanograms per milliliter (ng/mL)	Standard Deviation 0.378
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 0.5 hour	17.2 nanograms per milliliter (ng/mL)	Standard Deviation 3.44
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 16 hours	0.244 nanograms per milliliter (ng/mL)	Standard Deviation 0.488
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 24 hours	0.219 nanograms per milliliter (ng/mL)	Standard Deviation 0.342
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 72 hours	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 8 hours	1.16 nanograms per milliliter (ng/mL)	Standard Deviation 1.31
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 4 hours	4.17 nanograms per milliliter (ng/mL)	Standard Deviation 3.72
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 4 hours	7.16 nanograms per milliliter (ng/mL)	Standard Deviation 3.53
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 0 hour	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 1 hour	14.7 nanograms per milliliter (ng/mL)	Standard Deviation 3.8
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 16 hours	0.625 nanograms per milliliter (ng/mL)	Standard Deviation 0.586
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 4 hours	14.9 nanograms per milliliter (ng/mL)	Standard Deviation 6.75
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 0 hour	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 0.5 hour	69.1 nanograms per milliliter (ng/mL)	Standard Deviation 16.8
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 1 hour	48.9 nanograms per milliliter (ng/mL)	Standard Deviation 26.6
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 4 hours	25.2 nanograms per milliliter (ng/mL)	Standard Deviation 11.7
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 8 hours	3.89 nanograms per milliliter (ng/mL)	Standard Deviation 1.58
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 0 hour	0.914 nanograms per milliliter (ng/mL)	Standard Deviation 0.614
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 0.5 hour	71.3 nanograms per milliliter (ng/mL)	Standard Deviation 14
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 16 hours	1.15 nanograms per milliliter (ng/mL)	Standard Deviation 0.687
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 16 hours	2.47 nanograms per milliliter (ng/mL)	Standard Deviation 2.14
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 240 hours	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 0 hour	0.619 nanograms per milliliter (ng/mL)	Standard Deviation 0.462
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 2 hours	44.9 nanograms per milliliter (ng/mL)	Standard Deviation 14.5
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 8 hours	9.29 nanograms per milliliter (ng/mL)	Standard Deviation 4.62
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 2 hours	44.0 nanograms per milliliter (ng/mL)	Standard Deviation 18.5
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 1 hour	44.9 nanograms per milliliter (ng/mL)	Standard Deviation 18.3
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 72 hours	0.200 nanograms per milliliter (ng/mL)	Standard Deviation 0.347
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 2 hours	29.9 nanograms per milliliter (ng/mL)	Standard Deviation 12.3
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 24 hours	0.631 nanograms per milliliter (ng/mL)	Standard Deviation 0.63
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 8 hours	3.25 nanograms per milliliter (ng/mL)	Standard Deviation 1.84
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 24 hours	1.19 nanograms per milliliter (ng/mL)	Standard Deviation 0.633
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 24 hours	0.940 nanograms per milliliter (ng/mL)	Standard Deviation 0.561
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 0 hour	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 0.5 hour	72.2 nanograms per milliliter (ng/mL)	Standard Deviation 13
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 16 hours	1.50 nanograms per milliliter (ng/mL)	Standard Deviation 1.2
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 1 hour	58.8 nanograms per milliliter (ng/mL)	Standard Deviation 25.3
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 2 hours	30.1 nanograms per milliliter (ng/mL)	Standard Deviation 18.1
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 0.5 hour	77.9 nanograms per milliliter (ng/mL)	Standard Deviation 15.5
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 8 hours	10.0 nanograms per milliliter (ng/mL)	Standard Deviation 4.85
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 24 hours	0.221 nanograms per milliliter (ng/mL)	Standard Deviation 0.382
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 72 hours	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 1 hour	58.3 nanograms per milliliter (ng/mL)	Standard Deviation 11.8
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 4 hours	12.9 nanograms per milliliter (ng/mL)	Standard Deviation 7.19
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 4 hours	27.8 nanograms per milliliter (ng/mL)	Standard Deviation 10.6
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 0.5 hour	109 nanograms per milliliter (ng/mL)	Standard Deviation 29.6
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 16 hours	4.24 nanograms per milliliter (ng/mL)	Standard Deviation 3.6
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 24 hours	2.11 nanograms per milliliter (ng/mL)	Standard Deviation 1.45
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 0 hour	1.36 nanograms per milliliter (ng/mL)	Standard Deviation 0.589
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 0.5 hour	93.9 nanograms per milliliter (ng/mL)	Standard Deviation 22.2
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 1 hour	84.8 nanograms per milliliter (ng/mL)	Standard Deviation 23.7
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 2 hours	58.4 nanograms per milliliter (ng/mL)	Standard Deviation 19.3
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 4 hours	27.1 nanograms per milliliter (ng/mL)	Standard Deviation 10.4
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 8 hours	6.93 nanograms per milliliter (ng/mL)	Standard Deviation 3.91
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 16 hours	1.64 nanograms per milliliter (ng/mL)	Standard Deviation 0.597
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 24 hours	1.38 nanograms per milliliter (ng/mL)	Standard Deviation 0.697
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 72 hours	0.488 nanograms per milliliter (ng/mL)	Standard Deviation 0.376
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 240 hours	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 0 hour	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 1 hour	112 nanograms per milliliter (ng/mL)	Standard Deviation 24.5
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 2 hours	83.0 nanograms per milliliter (ng/mL)	Standard Deviation 19.6
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 4 hours	51.4 nanograms per milliliter (ng/mL)	Standard Deviation 15.9
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 8 hours	21.6 nanograms per milliliter (ng/mL)	Standard Deviation 7.61
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 16 hours	7.27 nanograms per milliliter (ng/mL)	Standard Deviation 4.49
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 24 hours	2.95 nanograms per milliliter (ng/mL)	Standard Deviation 1.61
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 0 hour	2.36 nanograms per milliliter (ng/mL)	Standard Deviation 2.29
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 0.5 hour	111 nanograms per milliliter (ng/mL)	Standard Deviation 26
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 1 hour	87.6 nanograms per milliliter (ng/mL)	Standard Deviation 14.7
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 2 hours	65.2 nanograms per milliliter (ng/mL)	Standard Deviation 22.1
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 4 hours	32.0 nanograms per milliliter (ng/mL)	Standard Deviation 14
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 8 hours	6.67 nanograms per milliliter (ng/mL)	Standard Deviation 2.74
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 16 hours	1.65 nanograms per milliliter (ng/mL)	Standard Deviation 0.707
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 24 hours	1.38 nanograms per milliliter (ng/mL)	Standard Deviation 0.631
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 72 hours	0.498 nanograms per milliliter (ng/mL)	Standard Deviation 0.596
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 0 hour	8.24 nanograms per milliliter (ng/mL)	Standard Deviation 24.7
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 8 hours	16.5 nanograms per milliliter (ng/mL)	Standard Deviation 7.44
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 0.5 hour	105 nanograms per milliliter (ng/mL)	Standard Deviation 23.9
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 1 hour	94.6 nanograms per milliliter (ng/mL)	Standard Deviation 14.3
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 2 hours	74.5 nanograms per milliliter (ng/mL)	Standard Deviation 18.2
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 4 hours	45.1 nanograms per milliliter (ng/mL)	Standard Deviation 14
Part A, Dose Escalation: Nemvaleukin Alfa 8 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 240 hours	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part A, Dose Escalation: Nemvaleukin Alfa 8 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 8 hours	18.7 nanograms per milliliter (ng/mL)	Standard Deviation 9.48
Part A, Dose Escalation: Nemvaleukin Alfa 8 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 0 hour	2.24 nanograms per milliliter (ng/mL)	Standard Deviation 1.46
Part A, Dose Escalation: Nemvaleukin Alfa 8 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 4 hours	57.4 nanograms per milliliter (ng/mL)	Standard Deviation 11.9
Part A, Dose Escalation: Nemvaleukin Alfa 8 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 0 hour	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part A, Dose Escalation: Nemvaleukin Alfa 8 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 4 hours	24.2 nanograms per milliliter (ng/mL)	Standard Deviation 2.26
Part A, Dose Escalation: Nemvaleukin Alfa 8 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 72 hours	0.611 nanograms per milliliter (ng/mL)	Standard Deviation 0.625
Part A, Dose Escalation: Nemvaleukin Alfa 8 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 8 hours	5.74 nanograms per milliliter (ng/mL)	Standard Deviation 0.0933
Part A, Dose Escalation: Nemvaleukin Alfa 8 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 2 hours	59.0 nanograms per milliliter (ng/mL)	Standard Deviation 6.87
Part A, Dose Escalation: Nemvaleukin Alfa 8 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 1 hour	90.5 nanograms per milliliter (ng/mL)	Standard Deviation 16.3
Part A, Dose Escalation: Nemvaleukin Alfa 8 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 2 hours	66.4 nanograms per milliliter (ng/mL)	Standard Deviation 6.97
Part A, Dose Escalation: Nemvaleukin Alfa 8 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 0 hour	1.59 nanograms per milliliter (ng/mL)	Standard Deviation 0.692
Part A, Dose Escalation: Nemvaleukin Alfa 8 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 2 hours	76.9 nanograms per milliliter (ng/mL)	Standard Deviation 23.3
Part A, Dose Escalation: Nemvaleukin Alfa 8 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 4 hours	50.5 nanograms per milliliter (ng/mL)	Standard Deviation 16.2
Part A, Dose Escalation: Nemvaleukin Alfa 8 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 24 hours	3.21 nanograms per milliliter (ng/mL)	Standard Deviation 0.253
Part A, Dose Escalation: Nemvaleukin Alfa 8 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 0.5 hour	157 nanograms per milliliter (ng/mL)	Standard Deviation 56.8
Part A, Dose Escalation: Nemvaleukin Alfa 8 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 4 hours	29.1 nanograms per milliliter (ng/mL)	Standard Deviation 7.92
Part A, Dose Escalation: Nemvaleukin Alfa 8 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 1 hour	98.4 nanograms per milliliter (ng/mL)	Standard Deviation 10.5
Part A, Dose Escalation: Nemvaleukin Alfa 8 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 1 hour	132 nanograms per milliliter (ng/mL)	Standard Deviation 33
Part A, Dose Escalation: Nemvaleukin Alfa 8 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 8 hours	6.68 nanograms per milliliter (ng/mL)	Standard Deviation 1.85
Part A, Dose Escalation: Nemvaleukin Alfa 8 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 1 hour	105 nanograms per milliliter (ng/mL)	Standard Deviation 27.7
Part A, Dose Escalation: Nemvaleukin Alfa 8 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 8 hours	24.9 nanograms per milliliter (ng/mL)	Standard Deviation 9.77
Part A, Dose Escalation: Nemvaleukin Alfa 8 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 0.5 hour	113 nanograms per milliliter (ng/mL)	Standard Deviation 15.1
Part A, Dose Escalation: Nemvaleukin Alfa 8 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 0.5 hour	98.8 nanograms per milliliter (ng/mL)	Standard Deviation 34.7
Part A, Dose Escalation: Nemvaleukin Alfa 8 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 0.5 hour	112 nanograms per milliliter (ng/mL)	Standard Deviation 14.6
Part A, Dose Escalation: Nemvaleukin Alfa 8 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 0 hour	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part A, Dose Escalation: Nemvaleukin Alfa 8 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 72 hours	0.824 nanograms per milliliter (ng/mL)	Standard Deviation 0.333
Part A, Dose Escalation: Nemvaleukin Alfa 8 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 24 hours	1.81 nanograms per milliliter (ng/mL)	Standard Deviation 1.3
Part A, Dose Escalation: Nemvaleukin Alfa 8 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 2 hours	98.9 nanograms per milliliter (ng/mL)	Standard Deviation 21.8
Part A, Dose Escalation: Nemvaleukin Alfa 10 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 4 hours	28.0 nanograms per milliliter (ng/mL)	Standard Deviation 14
Part A, Dose Escalation: Nemvaleukin Alfa 10 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 72 hours	0.664 nanograms per milliliter (ng/mL)	Standard Deviation 0.597
Part A, Dose Escalation: Nemvaleukin Alfa 10 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 0 hour	2.36 nanograms per milliliter (ng/mL)	Standard Deviation 1.11
Part A, Dose Escalation: Nemvaleukin Alfa 10 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 0 hour	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part A, Dose Escalation: Nemvaleukin Alfa 10 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 8 hours	24.9 nanograms per milliliter (ng/mL)	Standard Deviation 13.1
Part A, Dose Escalation: Nemvaleukin Alfa 10 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 24 hours	2.51 nanograms per milliliter (ng/mL)	Standard Deviation 1.19
Part A, Dose Escalation: Nemvaleukin Alfa 10 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 0.5 hour	121 nanograms per milliliter (ng/mL)	Standard Deviation 40.4
Part A, Dose Escalation: Nemvaleukin Alfa 10 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 4 hours	62.1 nanograms per milliliter (ng/mL)	Standard Deviation 26.5
Part A, Dose Escalation: Nemvaleukin Alfa 10 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 8 hours	5.06 nanograms per milliliter (ng/mL)	Standard Deviation 1.68
Part A, Dose Escalation: Nemvaleukin Alfa 10 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 1 hour	78.4 nanograms per milliliter (ng/mL)	Standard Deviation 39.9
Part A, Dose Escalation: Nemvaleukin Alfa 10 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 0 hour	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part A, Dose Escalation: Nemvaleukin Alfa 10 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 2 hours	100 nanograms per milliliter (ng/mL)	Standard Deviation 27.1
Part A, Dose Escalation: Nemvaleukin Alfa 10 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 1 hour	70.3 nanograms per milliliter (ng/mL)	Standard Deviation 9.27
Part A, Dose Escalation: Nemvaleukin Alfa 10 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 4 hours	24.3 nanograms per milliliter (ng/mL)	Standard Deviation 11.6
Part A, Dose Escalation: Nemvaleukin Alfa 10 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 2 hours	49.9 nanograms per milliliter (ng/mL)	Standard Deviation 15.2
Part A, Dose Escalation: Nemvaleukin Alfa 10 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 72 hours	1.57 nanograms per milliliter (ng/mL)	Standard Deviation 0.584
Part A, Dose Escalation: Nemvaleukin Alfa 10 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 8 hours	31.2 nanograms per milliliter (ng/mL)	Standard Deviation 16.9
Part A, Dose Escalation: Nemvaleukin Alfa 10 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 240 hours	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part A, Dose Escalation: Nemvaleukin Alfa 10 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 8 hours	7.51 nanograms per milliliter (ng/mL)	Standard Deviation 3.23
Part A, Dose Escalation: Nemvaleukin Alfa 10 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 0.5 hour	91.2 nanograms per milliliter (ng/mL)	Standard Deviation 40.2
Part A, Dose Escalation: Nemvaleukin Alfa 10 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 1 hour	102 nanograms per milliliter (ng/mL)	Standard Deviation 33.2
Part A, Dose Escalation: Nemvaleukin Alfa 10 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 0.5 hour	148 nanograms per milliliter (ng/mL)	Standard Deviation 18.2
Part A, Dose Escalation: Nemvaleukin Alfa 10 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 0 hour	1.67 nanograms per milliliter (ng/mL)	Standard Deviation 0.531
Part A, Dose Escalation: Nemvaleukin Alfa 10 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 4 hours	52.5 nanograms per milliliter (ng/mL)	Standard Deviation 15.8
Part A, Dose Escalation: Nemvaleukin Alfa 10 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 1 hour	135 nanograms per milliliter (ng/mL)	Standard Deviation 33.9
Part A, Dose Escalation: Nemvaleukin Alfa 10 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 2 hours	66.2 nanograms per milliliter (ng/mL)	Standard Deviation 15.1
Part A, Dose Escalation: Nemvaleukin Alfa 10 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 24 hours	5.18 nanograms per milliliter (ng/mL)	Standard Deviation 4.2
Part A, Dose Escalation: Nemvaleukin Alfa 10 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 0.5 hour	104 nanograms per milliliter (ng/mL)	Standard Deviation 13
Part A, Dose Escalation: Nemvaleukin Alfa 10 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 2 hours	85.9 nanograms per milliliter (ng/mL)	Standard Deviation 26.8
Part B, Dose Expansion, Melanoma: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 1 hour	78.0 nanograms per milliliter (ng/mL)	Standard Deviation 29.5
Part B, Dose Expansion, Melanoma: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 4 hours	46.8 nanograms per milliliter (ng/mL)	Standard Deviation 16.5
Part B, Dose Expansion, Melanoma: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 0.5 hour	85.1 nanograms per milliliter (ng/mL)	Standard Deviation 28.1
Part B, Dose Expansion, Melanoma: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 72 hours	0.578 nanograms per milliliter (ng/mL)	Standard Deviation 0.475
Part B, Dose Expansion, Melanoma: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 8 hours	7.94 nanograms per milliliter (ng/mL)	Standard Deviation 6.53
Part B, Dose Expansion, Melanoma: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 0.5 hour	102 nanograms per milliliter (ng/mL)	Standard Deviation 36.1
Part B, Dose Expansion, Melanoma: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 2 hours	76.7 nanograms per milliliter (ng/mL)	Standard Deviation 26.5
Part B, Dose Expansion, Melanoma: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 24 hours	2.03 nanograms per milliliter (ng/mL)	Standard Deviation 1.69
Part B, Dose Expansion, Melanoma: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 1 hour	93.3 nanograms per milliliter (ng/mL)	Standard Deviation 34.9
Part B, Dose Expansion, Melanoma: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 1 hour	101 nanograms per milliliter (ng/mL)	Standard Deviation 32.3
Part B, Dose Expansion, Melanoma: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 0.5 hour	174 nanograms per milliliter (ng/mL)	Standard Deviation 372
Part B, Dose Expansion, Melanoma: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 8 hours	26.8 nanograms per milliliter (ng/mL)	Standard Deviation 35.4
Part B, Dose Expansion, Melanoma: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 2 hours	77.4 nanograms per milliliter (ng/mL)	Standard Deviation 21.5
Part B, Dose Expansion, Melanoma: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 0 hour	2.11 nanograms per milliliter (ng/mL)	Standard Deviation 13.7
Part B, Dose Expansion, Melanoma: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 4 hours	27.6 nanograms per milliliter (ng/mL)	Standard Deviation 8.71
Part B, Dose Expansion, Melanoma: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 4 hours	50.1 nanograms per milliliter (ng/mL)	Standard Deviation 16.2
Part B, Dose Expansion, Melanoma: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 0 hour	0.0137 nanograms per milliliter (ng/mL)	Standard Deviation 0.0917
Part B, Dose Expansion, Melanoma: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 0 hour	1.58 nanograms per milliliter (ng/mL)	Standard Deviation 0.653
Part B, Dose Expansion, Melanoma: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 72 hours	0.623 nanograms per milliliter (ng/mL)	Standard Deviation 0.973
Part B, Dose Expansion, Melanoma: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 0.5 hour	153 nanograms per milliliter (ng/mL)	Standard Deviation 300
Part B, Dose Expansion, Melanoma: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 8 hours	31.8 nanograms per milliliter (ng/mL)	Standard Deviation 28.9
Part B, Dose Expansion, Melanoma: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 8 hours	6.78 nanograms per milliliter (ng/mL)	Standard Deviation 3.25
Part B, Dose Expansion, Melanoma: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 4 hours	39.4 nanograms per milliliter (ng/mL)	Standard Deviation 43.2
Part B, Dose Expansion, Melanoma: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 2 hours	55.3 nanograms per milliliter (ng/mL)	Standard Deviation 20.9
Part B, Dose Expansion, Melanoma: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 24 hours	3.64 nanograms per milliliter (ng/mL)	Standard Deviation 1.9
Part B, Dose Expansion, Melanoma: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 240 hours	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part B, Dose Expansion, Melanoma: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 2 hours	57.8 nanograms per milliliter (ng/mL)	Standard Deviation 20.2
Part B, Dose Expansion, Melanoma: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 1 hour	94.8 nanograms per milliliter (ng/mL)	Standard Deviation 104
Part B, Dose Expansion, Melanoma: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 0 hour	1.51 nanograms per milliliter (ng/mL)	Standard Deviation 0.654
Part B, Dose Expansion, RCC: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 8 hours	24.1 nanograms per milliliter (ng/mL)	Standard Deviation 8.09
Part B, Dose Expansion, RCC: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 24 hours	1.95 nanograms per milliliter (ng/mL)	Standard Deviation 0.854
Part B, Dose Expansion, RCC: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 2 hours	87.9 nanograms per milliliter (ng/mL)	Standard Deviation 23.5
Part B, Dose Expansion, RCC: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 1 hour	83.4 nanograms per milliliter (ng/mL)	Standard Deviation 19.4
Part B, Dose Expansion, RCC: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 8 hours	32.5 nanograms per milliliter (ng/mL)	Standard Deviation 7.83
Part B, Dose Expansion, RCC: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 24 hours	3.53 nanograms per milliliter (ng/mL)	Standard Deviation 1.25
Part B, Dose Expansion, RCC: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 4 hours	30.3 nanograms per milliliter (ng/mL)	Standard Deviation 6.2
Part B, Dose Expansion, RCC: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 1 hour	83.8 nanograms per milliliter (ng/mL)	Standard Deviation 14.8
Part B, Dose Expansion, RCC: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 0.5 hour	101 nanograms per milliliter (ng/mL)	Standard Deviation 29.2
Part B, Dose Expansion, RCC: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 2 hours	61.0 nanograms per milliliter (ng/mL)	Standard Deviation 14.3
Part B, Dose Expansion, RCC: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 0 hour	1.96 nanograms per milliliter (ng/mL)	Standard Deviation 0.987
Part B, Dose Expansion, RCC: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 8 hours	6.49 nanograms per milliliter (ng/mL)	Standard Deviation 2.96
Part B, Dose Expansion, RCC: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 4 hours	29.1 nanograms per milliliter (ng/mL)	Standard Deviation 10.4
Part B, Dose Expansion, RCC: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 0 hour	0.120 nanograms per milliliter (ng/mL)	Standard Deviation 0.41
Part B, Dose Expansion, RCC: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 1 hour	117 nanograms per milliliter (ng/mL)	Standard Deviation 19.9
Part B, Dose Expansion, RCC: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 72 hours	0.396 nanograms per milliliter (ng/mL)	Standard Deviation 0.45
Part B, Dose Expansion, RCC: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 4 hours	66.4 nanograms per milliliter (ng/mL)	Standard Deviation 15.9
Part B, Dose Expansion, RCC: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 1 hour	106 nanograms per milliliter (ng/mL)	Standard Deviation 30.3
Part B, Dose Expansion, RCC: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 4 hours	57.1 nanograms per milliliter (ng/mL)	Standard Deviation 14.9
Part B, Dose Expansion, RCC: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 0 hour	0.0329 nanograms per milliliter (ng/mL)	Standard Deviation 0.171
Part B, Dose Expansion, RCC: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 0.5 hour	131 nanograms per milliliter (ng/mL)	Standard Deviation 51.3
Part B, Dose Expansion, RCC: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 0 hour	1.72 nanograms per milliliter (ng/mL)	Standard Deviation 0.599
Part B, Dose Expansion, RCC: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 0.5 hour	101 nanograms per milliliter (ng/mL)	Standard Deviation 18.6
Part B, Dose Expansion, RCC: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 72 hours	0.538 nanograms per milliliter (ng/mL)	Standard Deviation 0.383
Part B, Dose Expansion, RCC: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 8 hours	6.33 nanograms per milliliter (ng/mL)	Standard Deviation 2.04
Part B, Dose Expansion, RCC: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 2 hours	97.6 nanograms per milliliter (ng/mL)	Standard Deviation 21.7
Part B, Dose Expansion, RCC: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 2 hours	62.0 nanograms per milliliter (ng/mL)	Standard Deviation 17.8
Part B, Dose Expansion, RCC: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 0.5 hour	123 nanograms per milliliter (ng/mL)	Standard Deviation 31.7
Part B, Dose Expansion, RCC: Nemvaleukin Alfa 6 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 240 hours	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part C, Combination Therapy, Safety Run-in: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 0 hour	0.209 nanograms per milliliter (ng/mL)	Standard Deviation 0.361
Part C, Combination Therapy, Safety Run-in: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 8 hours	2.51 nanograms per milliliter (ng/mL)	—
Part C, Combination Therapy, Safety Run-in: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 0.5 hour	15.8 nanograms per milliliter (ng/mL)	Standard Deviation 2.82
Part C, Combination Therapy, Safety Run-in: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 8 hours	4.49 nanograms per milliliter (ng/mL)	Standard Deviation 1.26
Part C, Combination Therapy, Safety Run-in: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 8 hours	1.86 nanograms per milliliter (ng/mL)	Standard Deviation 0.257
Part C, Combination Therapy, Safety Run-in: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 1 hour	18.9 nanograms per milliliter (ng/mL)	Standard Deviation 2.5
Part C, Combination Therapy, Safety Run-in: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 1 hour	17.4 nanograms per milliliter (ng/mL)	Standard Deviation 5.33
Part C, Combination Therapy, Safety Run-in: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 0.5 hour	13.4 nanograms per milliliter (ng/mL)	Standard Deviation 3.07
Part C, Combination Therapy, Safety Run-in: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 4 hours	6.18 nanograms per milliliter (ng/mL)	Standard Deviation 0.687
Part C, Combination Therapy, Safety Run-in: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 0 hour	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part C, Combination Therapy, Safety Run-in: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 8 hours	1.47 nanograms per milliliter (ng/mL)	Standard Deviation 0.445
Part C, Combination Therapy, Safety Run-in: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 4 hours	7.00 nanograms per milliliter (ng/mL)	Standard Deviation 0.412
Part C, Combination Therapy, Safety Run-in: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 2 hours	10.3 nanograms per milliliter (ng/mL)	Standard Deviation 4.44
Part C, Combination Therapy, Safety Run-in: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 0.5 hour	19.5 nanograms per milliliter (ng/mL)	Standard Deviation 3.9
Part C, Combination Therapy, Safety Run-in: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 1 hour	13.7 nanograms per milliliter (ng/mL)	—
Part C, Combination Therapy, Safety Run-in: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 24 hours	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part C, Combination Therapy, Safety Run-in: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 1 hour	16.8 nanograms per milliliter (ng/mL)	Standard Deviation 5.53
Part C, Combination Therapy, Safety Run-in: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 4 hours	6.40 nanograms per milliliter (ng/mL)	Standard Deviation 2.13
Part C, Combination Therapy, Safety Run-in: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 24 hours	0.498 nanograms per milliliter (ng/mL)	Standard Deviation 0.704
Part C, Combination Therapy, Safety Run-in: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 2 hours	13.1 nanograms per milliliter (ng/mL)	Standard Deviation 0.626
Part C, Combination Therapy, Safety Run-in: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 0 hour	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part C, Combination Therapy, Safety Run-in: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 0.5 hour	18.6 nanograms per milliliter (ng/mL)	Standard Deviation 3.94
Part C, Combination Therapy, Safety Run-in: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 4 hours	8.74 nanograms per milliliter (ng/mL)	Standard Deviation 1.5
Part C, Combination Therapy, Safety Run-in: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 2 hours	14.0 nanograms per milliliter (ng/mL)	Standard Deviation 2.74
Part C, Combination Therapy, Safety Run-in: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 0 hour	0.180 nanograms per milliliter (ng/mL)	Standard Deviation 0.312
Part C, Combination Therapy, Safety Run-in: Nemvaleukin Alfa 1 mcg/kg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 2 hours	11.3 nanograms per milliliter (ng/mL)	Standard Deviation 1.39
Part C, Combination Therapy, Cohort 1 +Safety Run-in: Nemvaleukin Alfa 3 mcg/kg+Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 8 hours	28.2 nanograms per milliliter (ng/mL)	Standard Deviation 64.5
Part C, Combination Therapy, Cohort 1 +Safety Run-in: Nemvaleukin Alfa 3 mcg/kg+Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 0 hour	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part C, Combination Therapy, Cohort 1 +Safety Run-in: Nemvaleukin Alfa 3 mcg/kg+Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 0.5 hour	67.1 nanograms per milliliter (ng/mL)	Standard Deviation 14.9
Part C, Combination Therapy, Cohort 1 +Safety Run-in: Nemvaleukin Alfa 3 mcg/kg+Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 1 hour	50.0 nanograms per milliliter (ng/mL)	Standard Deviation 22.3
Part C, Combination Therapy, Cohort 1 +Safety Run-in: Nemvaleukin Alfa 3 mcg/kg+Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 4 hours	8.11 nanograms per milliliter (ng/mL)	Standard Deviation 2.77
Part C, Combination Therapy, Cohort 1 +Safety Run-in: Nemvaleukin Alfa 3 mcg/kg+Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 2 hours	38.7 nanograms per milliliter (ng/mL)	Standard Deviation 17.4
Part C, Combination Therapy, Cohort 1 +Safety Run-in: Nemvaleukin Alfa 3 mcg/kg+Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 4 hours	21.9 nanograms per milliliter (ng/mL)	Standard Deviation 7.94
Part C, Combination Therapy, Cohort 1 +Safety Run-in: Nemvaleukin Alfa 3 mcg/kg+Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 8 hours	9.63 nanograms per milliliter (ng/mL)	Standard Deviation 4.37
Part C, Combination Therapy, Cohort 1 +Safety Run-in: Nemvaleukin Alfa 3 mcg/kg+Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 2 hours	21.3 nanograms per milliliter (ng/mL)	Standard Deviation 4.81
Part C, Combination Therapy, Cohort 1 +Safety Run-in: Nemvaleukin Alfa 3 mcg/kg+Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 16 hours	0.00 nanograms per milliliter (ng/mL)	—
Part C, Combination Therapy, Cohort 1 +Safety Run-in: Nemvaleukin Alfa 3 mcg/kg+Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 24 hours	1.46 nanograms per milliliter (ng/mL)	Standard Deviation 0.803
Part C, Combination Therapy, Cohort 1 +Safety Run-in: Nemvaleukin Alfa 3 mcg/kg+Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 0 hour	0.416 nanograms per milliliter (ng/mL)	Standard Deviation 0.538
Part C, Combination Therapy, Cohort 1 +Safety Run-in: Nemvaleukin Alfa 3 mcg/kg+Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 0.5 hour	49.5 nanograms per milliliter (ng/mL)	Standard Deviation 19.7
Part C, Combination Therapy, Cohort 1 +Safety Run-in: Nemvaleukin Alfa 3 mcg/kg+Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 1 hour	33.8 nanograms per milliliter (ng/mL)	Standard Deviation 7.91
Part C, Combination Therapy, Cohort 1 +Safety Run-in: Nemvaleukin Alfa 3 mcg/kg+Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 1 hour	45.6 nanograms per milliliter (ng/mL)	Standard Deviation 22.3
Part C, Combination Therapy, Cohort 1 +Safety Run-in: Nemvaleukin Alfa 3 mcg/kg+Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 2 hours	31.8 nanograms per milliliter (ng/mL)	Standard Deviation 17
Part C, Combination Therapy, Cohort 1 +Safety Run-in: Nemvaleukin Alfa 3 mcg/kg+Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 4 hours	13.1 nanograms per milliliter (ng/mL)	Standard Deviation 11.7
Part C, Combination Therapy, Cohort 1 +Safety Run-in: Nemvaleukin Alfa 3 mcg/kg+Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 0.5 hour	44.3 nanograms per milliliter (ng/mL)	Standard Deviation 9.53
Part C, Combination Therapy, Cohort 1 +Safety Run-in: Nemvaleukin Alfa 3 mcg/kg+Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 4 hours	19.5 nanograms per milliliter (ng/mL)	Standard Deviation 4.9
Part C, Combination Therapy, Cohort 1 +Safety Run-in: Nemvaleukin Alfa 3 mcg/kg+Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 8 hours	3.39 nanograms per milliliter (ng/mL)	Standard Deviation 3.39
Part C, Combination Therapy, Cohort 1 +Safety Run-in: Nemvaleukin Alfa 3 mcg/kg+Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 0 hour	0.756 nanograms per milliliter (ng/mL)	Standard Deviation 0.786
Part C, Combination Therapy, Cohort 1 +Safety Run-in: Nemvaleukin Alfa 3 mcg/kg+Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 0 hour	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part C, Combination Therapy, Cohort 1 +Safety Run-in: Nemvaleukin Alfa 3 mcg/kg+Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 8 hours	8.66 nanograms per milliliter (ng/mL)	Standard Deviation 4.83
Part C, Combination Therapy, Cohort 1 +Safety Run-in: Nemvaleukin Alfa 3 mcg/kg+Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 0.5 hour	56.3 nanograms per milliliter (ng/mL)	Standard Deviation 9.99
Part C, Combination Therapy, Cohort 1 +Safety Run-in: Nemvaleukin Alfa 3 mcg/kg+Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 24 hours	0.737 nanograms per milliliter (ng/mL)	Standard Deviation 0.518
Part C, Combination Therapy, Cohort 1 +Safety Run-in: Nemvaleukin Alfa 3 mcg/kg+Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 1 hour	48.2 nanograms per milliliter (ng/mL)	Standard Deviation 13.7
Part C, Combination Therapy, Cohort 1 +Safety Run-in: Nemvaleukin Alfa 3 mcg/kg+Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 2 hours	35.6 nanograms per milliliter (ng/mL)	Standard Deviation 8.32
Part C, Combination Therapy, Cohort 2: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 2 hours	42.5 nanograms per milliliter (ng/mL)	Standard Deviation 9.2
Part C, Combination Therapy, Cohort 2: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 24 hours	1.06 nanograms per milliliter (ng/mL)	Standard Deviation 1.06
Part C, Combination Therapy, Cohort 2: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 8 hours	10.2 nanograms per milliliter (ng/mL)	Standard Deviation 2.88
Part C, Combination Therapy, Cohort 2: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 8 hours	3.33 nanograms per milliliter (ng/mL)	Standard Deviation 1.87
Part C, Combination Therapy, Cohort 2: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 0 hour	1.10 nanograms per milliliter (ng/mL)	Standard Deviation 0.965
Part C, Combination Therapy, Cohort 2: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 1 hour	69.8 nanograms per milliliter (ng/mL)	Standard Deviation 124
Part C, Combination Therapy, Cohort 2: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 0.5 hour	61.7 nanograms per milliliter (ng/mL)	Standard Deviation 13.4
Part C, Combination Therapy, Cohort 2: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 0 hour	2.14 nanograms per milliliter (ng/mL)	Standard Deviation 6.54
Part C, Combination Therapy, Cohort 2: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 0.5 hour	57.8 nanograms per milliliter (ng/mL)	Standard Deviation 15.4
Part C, Combination Therapy, Cohort 2: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 0 hour	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part C, Combination Therapy, Cohort 2: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 2 hours	28.6 nanograms per milliliter (ng/mL)	Standard Deviation 9.1
Part C, Combination Therapy, Cohort 2: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 1 hour	47.2 nanograms per milliliter (ng/mL)	Standard Deviation 12.7
Part C, Combination Therapy, Cohort 2: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 8 hours	3.41 nanograms per milliliter (ng/mL)	Standard Deviation 1.66
Part C, Combination Therapy, Cohort 2: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 24 hours	1.64 nanograms per milliliter (ng/mL)	Standard Deviation 1.44
Part C, Combination Therapy, Cohort 2: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 0 hour	0.0170 nanograms per milliliter (ng/mL)	Standard Deviation 0.0945
Part C, Combination Therapy, Cohort 2: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 4 hours	13.2 nanograms per milliliter (ng/mL)	Standard Deviation 5.51
Part C, Combination Therapy, Cohort 2: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 4 hours	12.0 nanograms per milliliter (ng/mL)	Standard Deviation 4.47
Part C, Combination Therapy, Cohort 2: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 2 hours	38.8 nanograms per milliliter (ng/mL)	Standard Deviation 9.33
Part C, Combination Therapy, Cohort 2: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 240 hours	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part C, Combination Therapy, Cohort 2: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 4 hours	25.6 nanograms per milliliter (ng/mL)	Standard Deviation 5.22
Part C, Combination Therapy, Cohort 2: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 8 hours	7.91 nanograms per milliliter (ng/mL)	Standard Deviation 3.47
Part C, Combination Therapy, Cohort 2: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 0.5 hour	58.3 nanograms per milliliter (ng/mL)	Standard Deviation 25.3
Part C, Combination Therapy, Cohort 2: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 2 hours	30.6 nanograms per milliliter (ng/mL)	Standard Deviation 9.57
Part C, Combination Therapy, Cohort 2: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 0.5 hour	64.2 nanograms per milliliter (ng/mL)	Standard Deviation 60.1
Part C, Combination Therapy, Cohort 2: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 1 hour	51.5 nanograms per milliliter (ng/mL)	Standard Deviation 10
Part C, Combination Therapy, Cohort 2: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 4 hours	25.1 nanograms per milliliter (ng/mL)	Standard Deviation 12.7
Part C, Combination Therapy, Cohort 2: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 1 hour	56.3 nanograms per milliliter (ng/mL)	Standard Deviation 11.2
Part C, Combination Therapy, Cohort 3: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 1 hour	54.2 nanograms per milliliter (ng/mL)	Standard Deviation 14.2
Part C, Combination Therapy, Cohort 3: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 1 hour	42.7 nanograms per milliliter (ng/mL)	Standard Deviation 12.9
Part C, Combination Therapy, Cohort 3: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 0 hour	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part C, Combination Therapy, Cohort 3: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 72 hours	0.210 nanograms per milliliter (ng/mL)	Standard Deviation 0.419
Part C, Combination Therapy, Cohort 3: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 8 hours	10.8 nanograms per milliliter (ng/mL)	Standard Deviation 4.41
Part C, Combination Therapy, Cohort 3: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 8 hours	4.85 nanograms per milliliter (ng/mL)	Standard Deviation 3.63
Part C, Combination Therapy, Cohort 3: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 8 hours	8.85 nanograms per milliliter (ng/mL)	Standard Deviation 3.92
Part C, Combination Therapy, Cohort 3: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 0 hour	0.922 nanograms per milliliter (ng/mL)	Standard Deviation 0.67
Part C, Combination Therapy, Cohort 3: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 4 hours	24.0 nanograms per milliliter (ng/mL)	Standard Deviation 7.15
Part C, Combination Therapy, Cohort 3: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 1 hour	47.3 nanograms per milliliter (ng/mL)	Standard Deviation 12.2
Part C, Combination Therapy, Cohort 3: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 240 hours	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part C, Combination Therapy, Cohort 3: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 0.5 hour	79.6 nanograms per milliliter (ng/mL)	Standard Deviation 93.1
Part C, Combination Therapy, Cohort 3: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 0.5 hour	71.5 nanograms per milliliter (ng/mL)	Standard Deviation 51.7
Part C, Combination Therapy, Cohort 3: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 24 hours	1.64 nanograms per milliliter (ng/mL)	Standard Deviation 1.42
Part C, Combination Therapy, Cohort 3: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 4 hours	14.8 nanograms per milliliter (ng/mL)	Standard Deviation 6
Part C, Combination Therapy, Cohort 3: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 8 hours	3.99 nanograms per milliliter (ng/mL)	Standard Deviation 1.69
Part C, Combination Therapy, Cohort 3: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 2 hours	31.8 nanograms per milliliter (ng/mL)	Standard Deviation 9.39
Part C, Combination Therapy, Cohort 3: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 2 hours	43.6 nanograms per milliliter (ng/mL)	Standard Deviation 11.5
Part C, Combination Therapy, Cohort 3: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 0 hour	2.16 nanograms per milliliter (ng/mL)	Standard Deviation 3.95
Part C, Combination Therapy, Cohort 3: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 0 hour	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part C, Combination Therapy, Cohort 3: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 24 hours	1.16 nanograms per milliliter (ng/mL)	Standard Deviation 0.777
Part C, Combination Therapy, Cohort 3: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 72 hours	0.00 nanograms per milliliter (ng/mL)	—
Part C, Combination Therapy, Cohort 3: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 2 hours	29.9 nanograms per milliliter (ng/mL)	Standard Deviation 9.94
Part C, Combination Therapy, Cohort 3: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 1 hour	61.6 nanograms per milliliter (ng/mL)	Standard Deviation 25.5
Part C, Combination Therapy, Cohort 3: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 0.5 hour	63.6 nanograms per milliliter (ng/mL)	Standard Deviation 41.8
Part C, Combination Therapy, Cohort 3: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 4 hours	17.2 nanograms per milliliter (ng/mL)	Standard Deviation 18.5
Part C, Combination Therapy, Cohort 3: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 2 hours	38.3 nanograms per milliliter (ng/mL)	Standard Deviation 11.1
Part C, Combination Therapy, Cohort 3: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 4 hours	27.6 nanograms per milliliter (ng/mL)	Standard Deviation 7.91
Part C, Combination Therapy, Cohort 3: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 0.5 hour	58.8 nanograms per milliliter (ng/mL)	Standard Deviation 38.5
Part C, Combination Therapy, Rollover, Cohort 4: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 0.5 hour	52.7 nanograms per milliliter (ng/mL)	Standard Deviation 14.4
Part C, Combination Therapy, Rollover, Cohort 4: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 4 hours	13.3 nanograms per milliliter (ng/mL)	Standard Deviation 5.22
Part C, Combination Therapy, Rollover, Cohort 4: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 1 hour	47.8 nanograms per milliliter (ng/mL)	Standard Deviation 13
Part C, Combination Therapy, Rollover, Cohort 4: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 24 hours	1.29 nanograms per milliliter (ng/mL)	Standard Deviation 0.749
Part C, Combination Therapy, Rollover, Cohort 4: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 0.5 hour	62.5 nanograms per milliliter (ng/mL)	Standard Deviation 20.2
Part C, Combination Therapy, Rollover, Cohort 4: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 2 hours	27.4 nanograms per milliliter (ng/mL)	Standard Deviation 9.8
Part C, Combination Therapy, Rollover, Cohort 4: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 0.5 hour	61.1 nanograms per milliliter (ng/mL)	Standard Deviation 30.1
Part C, Combination Therapy, Rollover, Cohort 4: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 24 hours	1.15 nanograms per milliliter (ng/mL)	Standard Deviation 1.4
Part C, Combination Therapy, Rollover, Cohort 4: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 16 hours	4.95 nanograms per milliliter (ng/mL)	—
Part C, Combination Therapy, Rollover, Cohort 4: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 2 hours	28.5 nanograms per milliliter (ng/mL)	Standard Deviation 9.68
Part C, Combination Therapy, Rollover, Cohort 4: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 4 hours	13.0 nanograms per milliliter (ng/mL)	Standard Deviation 7.01
Part C, Combination Therapy, Rollover, Cohort 4: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 0 hour	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part C, Combination Therapy, Rollover, Cohort 4: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 8 hours	3.94 nanograms per milliliter (ng/mL)	Standard Deviation 1.97
Part C, Combination Therapy, Rollover, Cohort 4: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 8 hours	10.8 nanograms per milliliter (ng/mL)	Standard Deviation 4.29
Part C, Combination Therapy, Rollover, Cohort 4: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 8 hours	3.26 nanograms per milliliter (ng/mL)	Standard Deviation 1.32
Part C, Combination Therapy, Rollover, Cohort 4: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 16 hours	1.97 nanograms per milliliter (ng/mL)	—
Part C, Combination Therapy, Rollover, Cohort 4: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 1 hour	41.9 nanograms per milliliter (ng/mL)	Standard Deviation 11.7
Part C, Combination Therapy, Rollover, Cohort 4: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 0 hour	1.01 nanograms per milliliter (ng/mL)	Standard Deviation 1.71
Part C, Combination Therapy, Rollover, Cohort 4: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 4 hours	21.4 nanograms per milliliter (ng/mL)	Standard Deviation 8.75
Part C, Combination Therapy, Rollover, Cohort 4: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 1 hour	42.3 nanograms per milliliter (ng/mL)	Standard Deviation 15.5
Part C, Combination Therapy, Rollover, Cohort 4: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 72 hours	0.103 nanograms per milliliter (ng/mL)	Standard Deviation 0.273
Part C, Combination Therapy, Rollover, Cohort 4: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 4 hours	26.4 nanograms per milliliter (ng/mL)	Standard Deviation 8.67
Part C, Combination Therapy, Rollover, Cohort 4: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 0 hour	2.10 nanograms per milliliter (ng/mL)	Standard Deviation 9.24
Part C, Combination Therapy, Rollover, Cohort 4: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 2 hours	42.6 nanograms per milliliter (ng/mL)	Standard Deviation 13.8
Part C, Combination Therapy, Rollover, Cohort 4: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 72 hours	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part C, Combination Therapy, Rollover, Cohort 4: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 8 hours	7.40 nanograms per milliliter (ng/mL)	Standard Deviation 3.67
Part C, Combination Therapy, Rollover, Cohort 4: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 2 hours	37.1 nanograms per milliliter (ng/mL)	Standard Deviation 10.5
Part C, Combination Therapy, Rollover, Cohort 4: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 0 hour	0.933 nanograms per milliliter (ng/mL)	Standard Deviation 0.529
Part C, Combination Therapy, Rollover, Cohort 4: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 1 hour	57.5 nanograms per milliliter (ng/mL)	Standard Deviation 17.9
Part C, Combination Therapy, Rollover, Cohort 4: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 240 hours	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part C, Combination Therapy, Rollover, Cohort 4: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 0.5 hour	55.7 nanograms per milliliter (ng/mL)	Standard Deviation 22.7
Part C, Combination Therapy, Cohort 5: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 8 hours	11.8 nanograms per milliliter (ng/mL)	Standard Deviation 11.9
Part C, Combination Therapy, Cohort 5: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 2 hours	35.6 nanograms per milliliter (ng/mL)	Standard Deviation 30.6
Part C, Combination Therapy, Cohort 5: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 24 hours	2.94 nanograms per milliliter (ng/mL)	Standard Deviation 6.88
Part C, Combination Therapy, Cohort 5: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 2 hours	34.0 nanograms per milliliter (ng/mL)	Standard Deviation 18.8
Part C, Combination Therapy, Cohort 5: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 1 hour	43.0 nanograms per milliliter (ng/mL)	Standard Deviation 27.4
Part C, Combination Therapy, Cohort 5: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 4 hours	25.2 nanograms per milliliter (ng/mL)	Standard Deviation 32.6
Part C, Combination Therapy, Cohort 5: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 8 hours	12.8 nanograms per milliliter (ng/mL)	Standard Deviation 18.3
Part C, Combination Therapy, Cohort 5: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 4 hours	17.7 nanograms per milliliter (ng/mL)	Standard Deviation 16.2
Part C, Combination Therapy, Cohort 5: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 72 hours	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part C, Combination Therapy, Cohort 5: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 240 hours	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part C, Combination Therapy, Cohort 5: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 4 hours	22.5 nanograms per milliliter (ng/mL)	Standard Deviation 13.6
Part C, Combination Therapy, Cohort 5: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 0.5 hour	56.7 nanograms per milliliter (ng/mL)	Standard Deviation 31.1
Part C, Combination Therapy, Cohort 5: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 0.5 hour	51.1 nanograms per milliliter (ng/mL)	Standard Deviation 28
Part C, Combination Therapy, Cohort 5: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 2 hours	36.7 nanograms per milliliter (ng/mL)	Standard Deviation 27.9
Part C, Combination Therapy, Cohort 5: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 0 hour	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part C, Combination Therapy, Cohort 5: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 1 hour	49.9 nanograms per milliliter (ng/mL)	Standard Deviation 37
Part C, Combination Therapy, Cohort 5: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 72 hours	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part C, Combination Therapy, Cohort 5: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 0 hour	4.17 nanograms per milliliter (ng/mL)	Standard Deviation 8.72
Part C, Combination Therapy, Cohort 5: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 0 hour	3.90 nanograms per milliliter (ng/mL)	Standard Deviation 9.89
Part C, Combination Therapy, Cohort 5: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 24 hours	4.96 nanograms per milliliter (ng/mL)	Standard Deviation 11.7
Part C, Combination Therapy, Cohort 5: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 4 hours	24.1 nanograms per milliliter (ng/mL)	Standard Deviation 19.1
Part C, Combination Therapy, Cohort 5: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 8 hours	7.80 nanograms per milliliter (ng/mL)	Standard Deviation 12.3
Part C, Combination Therapy, Cohort 5: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 1 hour	45.0 nanograms per milliliter (ng/mL)	Standard Deviation 28.2
Part C, Combination Therapy, Cohort 5: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 0.5 hour	51.8 nanograms per milliliter (ng/mL)	Standard Deviation 29.6
Part C, Combination Therapy, Cohort 5: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 1 hour	48.1 nanograms per milliliter (ng/mL)	Standard Deviation 28.2
Part C, Combination Therapy, Cohort 5: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 16 hours	1.69 nanograms per milliliter (ng/mL)	—
Part C, Combination Therapy, Cohort 5: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 0 hour	0.0151 nanograms per milliliter (ng/mL)	Standard Deviation 0.0988
Part C, Combination Therapy, Cohort 5: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 8 hours	12.2 nanograms per milliliter (ng/mL)	Standard Deviation 19.7
Part C, Combination Therapy, Cohort 5: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 2 hours	39.6 nanograms per milliliter (ng/mL)	Standard Deviation 38.3
Part C, Combination Therapy, Cohort 5: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 0.5 hour	48.9 nanograms per milliliter (ng/mL)	Standard Deviation 19.8
Part C, Combination Therapy, Cohort 6: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 1 hour	105 nanograms per milliliter (ng/mL)	Standard Deviation 14.3
Part C, Combination Therapy, Cohort 6: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 1 hour	120 nanograms per milliliter (ng/mL)	Standard Deviation 22
Part C, Combination Therapy, Cohort 6: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 8 hours	27.7 nanograms per milliliter (ng/mL)	Standard Deviation 6.94
Part C, Combination Therapy, Cohort 6: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 0 hour	2.03 nanograms per milliliter (ng/mL)	Standard Deviation 0.979
Part C, Combination Therapy, Cohort 6: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 4 hours	28.4 nanograms per milliliter (ng/mL)	Standard Deviation 1.42
Part C, Combination Therapy, Cohort 6: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 2 hours	94.9 nanograms per milliliter (ng/mL)	Standard Deviation 19.7
Part C, Combination Therapy, Cohort 6: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 2 hours	92.6 nanograms per milliliter (ng/mL)	Standard Deviation 16.1
Part C, Combination Therapy, Cohort 6: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 0 hour	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part C, Combination Therapy, Cohort 6: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 0.5 hour	100 nanograms per milliliter (ng/mL)	Standard Deviation 20
Part C, Combination Therapy, Cohort 6: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 0 hour	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part C, Combination Therapy, Cohort 6: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 4 hours	29.8 nanograms per milliliter (ng/mL)	Standard Deviation 2.81
Part C, Combination Therapy, Cohort 6: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 0.5 hour	113 nanograms per milliliter (ng/mL)	Standard Deviation 16.8
Part C, Combination Therapy, Cohort 6: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 4 hours	54.9 nanograms per milliliter (ng/mL)	Standard Deviation 6.38
Part C, Combination Therapy, Cohort 6: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 2 hours	65.1 nanograms per milliliter (ng/mL)	Standard Deviation 0.651
Part C, Combination Therapy, Cohort 6: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 0.5 hour	120 nanograms per milliliter (ng/mL)	Standard Deviation 6.24
Part C, Combination Therapy, Cohort 6: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 1 hour	117 nanograms per milliliter (ng/mL)	Standard Deviation 17.2
Part C, Combination Therapy, Cohort 6: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 8 hours	24.3 nanograms per milliliter (ng/mL)	Standard Deviation 3.79
Part C, Combination Therapy, Cohort 6: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 240 hours	0.00 nanograms per milliliter (ng/mL)	—
Part C, Combination Therapy, Cohort 6: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 0.5 hour	118 nanograms per milliliter (ng/mL)	Standard Deviation 2.15
Part C, Combination Therapy, Cohort 6: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 2 hours	57.6 nanograms per milliliter (ng/mL)	Standard Deviation 10.5
Part C, Combination Therapy, Cohort 6: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 1 hour	86.3 nanograms per milliliter (ng/mL)	Standard Deviation 15
Part C, Combination Therapy, Cohort 6: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 24 hours	3.16 nanograms per milliliter (ng/mL)	Standard Deviation 1.58
Part C, Combination Therapy, Cohort 6: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 0 hour	1.45 nanograms per milliliter (ng/mL)	Standard Deviation 0.417
Part C, Combination Therapy, Cohort 6: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 8 hours	4.98 nanograms per milliliter (ng/mL)	Standard Deviation 1.92
Part C, Combination Therapy, Cohort 6: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 8 hours	20.2 nanograms per milliliter (ng/mL)	Standard Deviation 18.7
Part C, Combination Therapy, Cohort 6: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 24 hours	4.49 nanograms per milliliter (ng/mL)	Standard Deviation 2.06
Part C, Combination Therapy, Cohort 6: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 4 hours	63.8 nanograms per milliliter (ng/mL)	Standard Deviation 12.3
Part C, Combination Therapy, Cohort 7: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 8 hours	24.0 nanograms per milliliter (ng/mL)	Standard Deviation 11.5
Part C, Combination Therapy, Cohort 7: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 1 hour	90.9 nanograms per milliliter (ng/mL)	Standard Deviation 24.6
Part C, Combination Therapy, Cohort 7: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 1 hour	102 nanograms per milliliter (ng/mL)	Standard Deviation 29.5
Part C, Combination Therapy, Cohort 7: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 24 hours	13.8 nanograms per milliliter (ng/mL)	Standard Deviation 43
Part C, Combination Therapy, Cohort 7: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 2 hours	71.1 nanograms per milliliter (ng/mL)	Standard Deviation 23.8
Part C, Combination Therapy, Cohort 7: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 0.5 hour	100 nanograms per milliliter (ng/mL)	Standard Deviation 28.8
Part C, Combination Therapy, Cohort 7: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 4 hours	32.4 nanograms per milliliter (ng/mL)	Standard Deviation 13.5
Part C, Combination Therapy, Cohort 7: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 8 hours	30.2 nanograms per milliliter (ng/mL)	Standard Deviation 8.92
Part C, Combination Therapy, Cohort 7: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 8 hours	8.60 nanograms per milliliter (ng/mL)	Standard Deviation 5.71
Part C, Combination Therapy, Cohort 7: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 2 hours	59.9 nanograms per milliliter (ng/mL)	Standard Deviation 19.7
Part C, Combination Therapy, Cohort 7: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 0 hour	2.17 nanograms per milliliter (ng/mL)	Standard Deviation 1.46
Part C, Combination Therapy, Cohort 7: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 2 hours	84.4 nanograms per milliliter (ng/mL)	Standard Deviation 24.6
Part C, Combination Therapy, Cohort 7: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 4 hours	59.7 nanograms per milliliter (ng/mL)	Standard Deviation 15.5
Part C, Combination Therapy, Cohort 7: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 72 hours	0.610 nanograms per milliliter (ng/mL)	Standard Deviation 0.00778
Part C, Combination Therapy, Cohort 7: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 2 hours	93.5 nanograms per milliliter (ng/mL)	Standard Deviation 30.7
Part C, Combination Therapy, Cohort 7: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 0 hour	0.372 nanograms per milliliter (ng/mL)	Standard Deviation 1.36
Part C, Combination Therapy, Cohort 7: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 0 hour	2.67 nanograms per milliliter (ng/mL)	Standard Deviation 2.06
Part C, Combination Therapy, Cohort 7: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 24 hours	2.98 nanograms per milliliter (ng/mL)	Standard Deviation 1.51
Part C, Combination Therapy, Cohort 7: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 4 hours	54.7 nanograms per milliliter (ng/mL)	Standard Deviation 16.7
Part C, Combination Therapy, Cohort 7: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 1 hour	121 nanograms per milliliter (ng/mL)	Standard Deviation 32.2
Part C, Combination Therapy, Cohort 7: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 0.5 hour	137 nanograms per milliliter (ng/mL)	Standard Deviation 47.3
Part C, Combination Therapy, Cohort 7: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 1 hour	114 nanograms per milliliter (ng/mL)	Standard Deviation 29.2
Part C, Combination Therapy, Cohort 7: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 4 hours	30.8 nanograms per milliliter (ng/mL)	Standard Deviation 12.5
Part C, Combination Therapy, Cohort 7: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 0.5 hour	131 nanograms per milliliter (ng/mL)	Standard Deviation 52.7
Part C, Combination Therapy, Cohort 7: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 240 hours	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part C, Combination Therapy, Cohort 7: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 8 hours	9.78 nanograms per milliliter (ng/mL)	Standard Deviation 5.22
Part C, Combination Therapy, Cohort 7: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 0 hour	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part C, Combination Therapy, Cohort 7: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 72 hours	1.17 nanograms per milliliter (ng/mL)	Standard Deviation 0.409
Part C, Combination Therapy, Cohort 7: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 0.5 hour	111 nanograms per milliliter (ng/mL)	Standard Deviation 42.4
Part C, Combination Therapy, Cohort 7: Nemvaleukin 6 Alfa mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 4 hours	58.0 nanograms per milliliter (ng/mL)	Standard Deviation 8.5
Part C, Combination Therapy, Cohort 7: Nemvaleukin 6 Alfa mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 24 hours	3.19 nanograms per milliliter (ng/mL)	Standard Deviation 1.1
Part C, Combination Therapy, Cohort 7: Nemvaleukin 6 Alfa mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 8 hours	26.4 nanograms per milliliter (ng/mL)	Standard Deviation 6.55
Part C, Combination Therapy, Cohort 7: Nemvaleukin 6 Alfa mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 8 hours	8.47 nanograms per milliliter (ng/mL)	Standard Deviation 3.87
Part C, Combination Therapy, Cohort 7: Nemvaleukin 6 Alfa mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 0.5 hour	104 nanograms per milliliter (ng/mL)	Standard Deviation 1.86
Part C, Combination Therapy, Cohort 7: Nemvaleukin 6 Alfa mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 1 hour	86.3 nanograms per milliliter (ng/mL)	—
Part C, Combination Therapy, Cohort 7: Nemvaleukin 6 Alfa mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 0 hour	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part C, Combination Therapy, Cohort 7: Nemvaleukin 6 Alfa mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 1 hour	89.7 nanograms per milliliter (ng/mL)	Standard Deviation 4.66
Part C, Combination Therapy, Cohort 7: Nemvaleukin 6 Alfa mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 0 hour	0.00 nanograms per milliliter (ng/mL)	Standard Deviation 0
Part C, Combination Therapy, Cohort 7: Nemvaleukin 6 Alfa mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 2 hours	70.7 nanograms per milliliter (ng/mL)	Standard Deviation 5.51
Part C, Combination Therapy, Cohort 7: Nemvaleukin 6 Alfa mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 1 hour	89.8 nanograms per milliliter (ng/mL)	—
Part C, Combination Therapy, Cohort 7: Nemvaleukin 6 Alfa mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 72 hours	0.741 nanograms per milliliter (ng/mL)	—
Part C, Combination Therapy, Cohort 7: Nemvaleukin 6 Alfa mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 72 hours	0.989 nanograms per milliliter (ng/mL)	—
Part C, Combination Therapy, Cohort 7: Nemvaleukin 6 Alfa mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 4 hours	48.9 nanograms per milliliter (ng/mL)	Standard Deviation 12.6
Part C, Combination Therapy, Cohort 7: Nemvaleukin 6 Alfa mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 2 hours	67.3 nanograms per milliliter (ng/mL)	Standard Deviation 4.5
Part C, Combination Therapy, Cohort 7: Nemvaleukin 6 Alfa mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 0 hour	1.86 nanograms per milliliter (ng/mL)	Standard Deviation 0.354
Part C, Combination Therapy, Cohort 7: Nemvaleukin 6 Alfa mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 8 hours	7.22 nanograms per milliliter (ng/mL)	Standard Deviation 0.698
Part C, Combination Therapy, Cohort 7: Nemvaleukin 6 Alfa mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 4 hours	33.4 nanograms per milliliter (ng/mL)	Standard Deviation 7.99
Part C, Combination Therapy, Cohort 7: Nemvaleukin 6 Alfa mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 8 hours	18.7 nanograms per milliliter (ng/mL)	—
Part C, Combination Therapy, Cohort 7: Nemvaleukin 6 Alfa mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 2 hours	66.5 nanograms per milliliter (ng/mL)	Standard Deviation 4.01
Part C, Combination Therapy, Cohort 7: Nemvaleukin 6 Alfa mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 0.5 hour	103 nanograms per milliliter (ng/mL)	—
Part C, Combination Therapy, Cohort 7: Nemvaleukin 6 Alfa mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 24 hours	3.45 nanograms per milliliter (ng/mL)	Standard Deviation 1.59
Part C, Combination Therapy, Cohort 7: Nemvaleukin 6 Alfa mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 5: 0 hour	1.92 nanograms per milliliter (ng/mL)	Standard Deviation 0.336
Part C, Combination Therapy, Cohort 7: Nemvaleukin 6 Alfa mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 1 Day 1: 0.5 hour	89.3 nanograms per milliliter (ng/mL)	Standard Deviation 2.71
Part C, Combination Therapy, Cohort 7: Nemvaleukin 6 Alfa mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 1 hour	120 nanograms per milliliter (ng/mL)	Standard Deviation 5.86
Part C, Combination Therapy, Cohort 7: Nemvaleukin 6 Alfa mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 5: 4 hours	34.7 nanograms per milliliter (ng/mL)	Standard Deviation 8.12
Part C, Combination Therapy, Cohort 7: Nemvaleukin 6 Alfa mcg/kg + Pembrolizumab 200 mg	Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa	Cycle 2 Day 1: 2 hours	89.7 nanograms per milliliter (ng/mL)	Standard Deviation 5.33

Secondary

Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa

Cycle 1 length = 14 days for Part A and 21 days for Part B and C; Cycle 2 length= 21 days for all parts.

Arm	Measure	Group	Value (MEDIAN)
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 1 Day 1	0.60 hours
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 1 Day 5	0.70 hours
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 2 Day 5	0.63 hours
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 2 Day 1	0.67 hours
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 2 Day 5	0.57 hours
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 1 Day 5	0.60 hours
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 1 Day 1	0.63 hours
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 2 Day 1	0.73 hours
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 1 Day 1	0.55 hours
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 2 Day 5	0.55 hours
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 2 Day 1	0.53 hours
Part A, Dose Escalation: Nemvaleukin Alfa 1 mcg/kg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 1 Day 5	0.54 hours
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 2 Day 1	0.55 hours
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 1 Day 5	0.55 hours
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 1 Day 1	0.57 hours
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 2 Day 5	0.68 hours
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 2 Day 5	0.60 hours
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 1 Day 5	0.58 hours
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 2 Day 1	0.58 hours
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 1 Day 1	0.57 hours
Part A, Dose Escalation: Nemvaleukin Alfa 8 mcg/kg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 2 Day 5	0.58 hours
Part A, Dose Escalation: Nemvaleukin Alfa 8 mcg/kg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 2 Day 1	0.53 hours
Part A, Dose Escalation: Nemvaleukin Alfa 8 mcg/kg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 1 Day 1	0.57 hours
Part A, Dose Escalation: Nemvaleukin Alfa 8 mcg/kg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 1 Day 5	0.53 hours
Part A, Dose Escalation: Nemvaleukin Alfa 10 mcg/kg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 1 Day 1	0.51 hours
Part A, Dose Escalation: Nemvaleukin Alfa 10 mcg/kg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 2 Day 1	0.52 hours
Part A, Dose Escalation: Nemvaleukin Alfa 10 mcg/kg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 2 Day 5	0.52 hours
Part A, Dose Escalation: Nemvaleukin Alfa 10 mcg/kg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 1 Day 5	0.53 hours
Part B, Dose Expansion, Melanoma: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 1 Day 1	0.52 hours
Part B, Dose Expansion, Melanoma: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 2 Day 1	0.50 hours
Part B, Dose Expansion, Melanoma: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 2 Day 5	0.50 hours
Part B, Dose Expansion, Melanoma: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 1 Day 5	0.51 hours
Part B, Dose Expansion, RCC: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 1 Day 5	0.50 hours
Part B, Dose Expansion, RCC: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 2 Day 1	0.50 hours
Part B, Dose Expansion, RCC: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 2 Day 5	0.50 hours
Part B, Dose Expansion, RCC: Nemvaleukin Alfa 6 mcg/kg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 1 Day 1	0.50 hours
Part C, Combination Therapy, Safety Run-in: Nemvaleukin Alfa 1 mcg/kg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 1 Day 5	0.58 hours
Part C, Combination Therapy, Safety Run-in: Nemvaleukin Alfa 1 mcg/kg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 2 Day 1	0.71 hours
Part C, Combination Therapy, Safety Run-in: Nemvaleukin Alfa 1 mcg/kg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 2 Day 5	0.72 hours
Part C, Combination Therapy, Safety Run-in: Nemvaleukin Alfa 1 mcg/kg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 1 Day 1	0.75 hours
Part C, Combination Therapy, Cohort 1 +Safety Run-in: Nemvaleukin Alfa 3 mcg/kg+Pembrolizumab 200 mg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 1 Day 5	0.73 hours
Part C, Combination Therapy, Cohort 1 +Safety Run-in: Nemvaleukin Alfa 3 mcg/kg+Pembrolizumab 200 mg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 2 Day 5	0.68 hours
Part C, Combination Therapy, Cohort 1 +Safety Run-in: Nemvaleukin Alfa 3 mcg/kg+Pembrolizumab 200 mg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 2 Day 1	0.68 hours
Part C, Combination Therapy, Cohort 1 +Safety Run-in: Nemvaleukin Alfa 3 mcg/kg+Pembrolizumab 200 mg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 1 Day 1	0.73 hours
Part C, Combination Therapy, Cohort 2: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 1 Day 1	0.55 hours
Part C, Combination Therapy, Cohort 2: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 2 Day 5	0.55 hours
Part C, Combination Therapy, Cohort 2: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 2 Day 1	0.55 hours
Part C, Combination Therapy, Cohort 2: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 1 Day 5	0.57 hours
Part C, Combination Therapy, Cohort 3: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 1 Day 1	0.55 hours
Part C, Combination Therapy, Cohort 3: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 1 Day 5	0.53 hours
Part C, Combination Therapy, Cohort 3: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 2 Day 5	0.55 hours
Part C, Combination Therapy, Cohort 3: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 2 Day 1	0.53 hours
Part C, Combination Therapy, Rollover, Cohort 4: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 1 Day 1	0.52 hours
Part C, Combination Therapy, Rollover, Cohort 4: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 2 Day 1	0.53 hours
Part C, Combination Therapy, Rollover, Cohort 4: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 2 Day 5	0.50 hours
Part C, Combination Therapy, Rollover, Cohort 4: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 1 Day 5	0.55 hours
Part C, Combination Therapy, Cohort 5: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 1 Day 1	0.50 hours
Part C, Combination Therapy, Cohort 5: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 1 Day 5	0.50 hours
Part C, Combination Therapy, Cohort 5: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 2 Day 5	0.50 hours
Part C, Combination Therapy, Cohort 5: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 2 Day 1	0.50 hours
Part C, Combination Therapy, Cohort 6: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 2 Day 5	0.56 hours
Part C, Combination Therapy, Cohort 6: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 2 Day 1	0.55 hours
Part C, Combination Therapy, Cohort 6: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 1 Day 1	0.50 hours
Part C, Combination Therapy, Cohort 6: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 1 Day 5	0.58 hours
Part C, Combination Therapy, Cohort 7: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 1 Day 5	0.52 hours
Part C, Combination Therapy, Cohort 7: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 2 Day 5	0.52 hours
Part C, Combination Therapy, Cohort 7: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 1 Day 1	0.53 hours
Part C, Combination Therapy, Cohort 7: Nemvaleukin Alfa 6 mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 2 Day 1	0.52 hours
Part C, Combination Therapy, Cohort 7: Nemvaleukin 6 Alfa mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 1 Day 5	0.83 hours
Part C, Combination Therapy, Cohort 7: Nemvaleukin 6 Alfa mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 2 Day 1	1.00 hours
Part C, Combination Therapy, Cohort 7: Nemvaleukin 6 Alfa mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 2 Day 5	0.77 hours
Part C, Combination Therapy, Cohort 7: Nemvaleukin 6 Alfa mcg/kg + Pembrolizumab 200 mg	Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa	Cycle 1 Day 1	0.78 hours

Secondary

Parts B, and C: Duration of Response (DOR) Based on RECIST v1.1

Duration of response was defined as the time from the first documentation of response (CR or PR) to the first documentation of objective tumor progression or death due to any cause. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. PD: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

Time frame: From the first documentation of response (CR or PR) to the first documentation of objective tumor progression or death due to any cause (up to 40.3 months for Part B and up to 50.5 months for Part C)

Population: The antitumor evaluable population consisted of participants who complete 2 cycles of therapy and had at least one follow-up scan. Here, overall number of participants analyzed signified participants who had CR or PR.

Arm	Measure	Value (MEDIAN)
Part A, Dose Escalation: Nemvaleukin Alfa 0.1 mcg/kg	Parts B, and C: Duration of Response (DOR) Based on RECIST v1.1	18.43 weeks
Part A, Dose Escalation: Nemvaleukin Alfa 0.3 mcg/kg	Parts B, and C: Duration of Response (DOR) Based on RECIST v1.1	28.86 weeks
Part A, Dose Escalation: Nemvaleukin Alfa 3 mcg/kg	Parts B, and C: Duration of Response (DOR) Based on RECIST v1.1	35.14 weeks
Part A, Dose Escalation: Nemvaleukin Alfa 6 mcg/kg	Parts B, and C: Duration of Response (DOR) Based on RECIST v1.1	NA weeks
Part A, Dose Escalation: Nemvaleukin Alfa 8 mcg/kg	Parts B, and C: Duration of Response (DOR) Based on RECIST v1.1	63.14 weeks
Part A, Dose Escalation: Nemvaleukin Alfa 10 mcg/kg	Parts B, and C: Duration of Response (DOR) Based on RECIST v1.1	NA weeks
Part B, Dose Expansion, Melanoma: Nemvaleukin Alfa 6 mcg/kg	Parts B, and C: Duration of Response (DOR) Based on RECIST v1.1	NA weeks
Part B, Dose Expansion, RCC: Nemvaleukin Alfa 6 mcg/kg	Parts B, and C: Duration of Response (DOR) Based on RECIST v1.1	39.07 weeks
Part C, Combination Therapy, Safety Run-in: Nemvaleukin Alfa 1 mcg/kg	Parts B, and C: Duration of Response (DOR) Based on RECIST v1.1	27.86 weeks

Secondary

Parts B, and C: Immune DOR (iDOR) Based on iRECIST

iDOR was defined as the time from the first documentation of response (iCR or iPR) to the first documentation of objective tumor progression (immune confirmed progressive disease \[iCPD\]) or death due to any cause based on iRECIST.

Time frame: From first dose of study drug up to 40.3 months for Part B; up to 50.5 months for Part C

Source: ClinicalTrials.gov · Data processed: Feb 26, 2026

A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors

Conditions

Keywords

Brief summary

Detailed description

Related papers

Interventions

Sponsors

Study design

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Countries

Participant flow

Recruitment details

Pre-assignment details

Participants by arm

Withdrawals & dropouts

Baseline characteristics

Adverse events

Outcome results

Part A: Number of Participants With Dose-limiting Toxicities (DLTs) Based on Common Terminology Criteria for Adverse Events (CTCAE)

Parts A, B, and C: Number of Participants With TEAEs by Severity Grading

Parts A, B, and C: Number of Participants With Treatment-emergent Adverse Events (TEAEs)

Parts B and C: Overall Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1

Part B and Part C Cohorts C5, C6, C7: Durable Response Rate (DRR) Based on RECIST v.1.1

Part B and Part C Cohorts C5, C6, C7: Immune DRR (iDRR) Based on iRECIST

Part B and Part C Cohorts C5, C6, C7: Immune PFS (iPFS)

Part B and Part C Cohorts C5, C6, C7: Progression-free Survival (PFS) Based on RECIST v.1.1

Parts A, B and C: Area Under Concentration From Time Zero to the Last Quantifiable Concentration (AUClast) of Nemvaleukin Alfa

Parts A, B, and C: Disease Control Rate (DCR) Based on RECIST v.1.1

Parts A, B, and C: Immune DCR (iDCR) Based on iRECIST v1.1

Parts A, B, and C: Immune ORR (iORR) Based on Immune RECIST (iRECIST)

Parts A, B and C: Maximum Cell Count of Interferon-gamma (INF-γ) and Interleukin 6 (IL-6)

Parts A, B and C: Maximum Cell Count of Whole Blood FoxP3+ T Cells (Tregs), Total Cluster of Differentiation (CD)8+ T Cells and Natural Killer (NK) Cells

Parts A, B and C: Maximum Observed Serum Concentration (Cmax) of Nemvaleukin Alfa

Parts A, B, and C: Proportion of Positive Anti-Nemvaleukin Alfa Antibodies (ADA)

Parts A, B, and C: Serum Concentrations of Nemvaleukin Alfa

Parts A, B and C: Time to Reach Cmax (Tmax) of Nemvaleukin Alfa

Parts B, and C: Duration of Response (DOR) Based on RECIST v1.1

Parts B, and C: Immune DOR (iDOR) Based on iRECIST